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Abstract 
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis characterised by severe 
inflammation of the axial skeleton followed by bone formation that can lead to ankylosis. 
The mechanisms mediating the transition from inflammation to bone formation are poorly 
understood due to the limited availability of relevant bone samples. Therefore, we used the 
proteoglycan-induced spondylitis (PGISp) mouse model to delineate the morphological 
changes during axial disease development. This mouse model develops spondylitis 
followed by ankylosis, mimicking the clinical progression seen in patients with AS.  
The first part of this project aimed to characterise the disease progression across a 43-
week time-course in the PGISp mouse model. The principal assessment for analysing 
spinal disease was a semi-quantitative histological score that assessed joint inflammation, 
joint destruction (including intervertebral disc (IVD), cartilage and bone) and excessive 
tissue formation (peri-joint mesenchymal tissue expansion or fibrocartilage formation). 
Early inflammation initiated at the periphery of the IVD and was followed by varying levels 
of disc, cartilage and bone damage. In the advanced stages of disease, excessive tissue 
formation and ectopic chondrocyte expansion, ectopic bone and osteophyte formation 
were the key features. Abnormal tissue formation was always associated with IVD 
destruction, which was the result of inflammation, indicating that inflammation-derived IVD 
destruction is a prerequisite for induction of excessive tissue formation and the subsequent 
osteoproliferation.  
Current therapies for AS include non-steroidal anti-inflammatory drugs (NSAIDs), tumour 
necrosis factor (TNF) inhibitors and physiotherapy. However, these therapies aim to 
alleviate symptoms but cannot prevent syndesmophyte formation; hence new, more 
effective, therapeutic strategies are required. Genome-wide association studies have 
shown that AS is strongly associated with prostaglandin E2 (PGE2) receptor subtype 4 
(EP4), which plays regulatory roles in both inflammation and bone formation. The 
involvement of EP4 in AS has not been examined. The second objective of this thesis was 
to examine the hypothesis that blocking EP4 can suppress disease progression by 
inhibiting both inflammation and bone formation. PGISp mice were prophylactically 
administered with ONO-AE1-329 (an EP4 agonist) or ONO-AE2-227 (an EP4 antagonist) 
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for 16 weeks. Indomethacin, an NSAID, was included as a positive control of PGE2 
signalling inhibitor. None of the treatments significantly altered peripheral arthritis or axial 
disease progression. Use of EP4 agonist or antagonist did not change bone mineral 
density and bone mineral content as measured by dual-energy X-ray absorptiometry. The 
large variation of disease onset and features within each experimental group confounded 
the analysis. 
The third objective was to test the hypothesis that inflammation-derived IVD destruction is 
a prerequisite for excessive tissue formation. To suppress the onset and severity of 
inflammation development, a combination of high dose etanercept plus high dose 
prednisolone was administered in the initial stage of axial disease development. This anti-
inflammatory therapy was found to significantly suppress peripheral inflammation and 
delay disease onset. It also reduced axial inflammation and led to a trend toward reduced 
IVD destruction, bone erosion, cartilage damage and excessive tissue formation. 
Suppressing inflammation ameliorated disease progression supporting that early and 
aggressive anti-inflammatory intervention might mediate genuine clinical improvements 
with respect to structural damage.  
In conclusion, enthesitis and excessive cartilage/bone formation were the key features of 
the PGISp mouse, making it a suitable model for understanding the pathological 
mechanisms that are involved in the transition from inflammation to osteoproliferation. The 
IVD destruction driven by inflammation is a prerequisite for induction of osteoproliferation. 
Therefore, early intervention with anti-inflammatory therapy might prevent structural 
damage and further suppress excessive tissue formation. 
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1 Chapter 1: Literature review 
1-1 Clinical features of AS 
Ankylosing spondylitis (AS) is an auto-immune inflammatory arthritis belonging to the 
spondyloarthropathies (SpA) that affects 0.35-1% of the population in the United States 
[1]. SpA is a broad group of related diseases sharing similar clinical symptoms, such as 
axial disease, peripheral arthritis, enthesitis, dactylitis, uveitis, psoriasis and inflammatory 
bowel disease (IBD). Other diseases in the SpA spectrum are psoriatic arthritis, reactive 
arthritis, enteropathy-related spondylitis and arthritis, and undifferentiated SpA [2]. 
AS is the major subgroup of SpA and the prevalence in white European population is 0.5% 
[3]. Inflammation in the axial skeleton, including spine and sacroiliac (SI) joints, leads to 
morning stiffness, chronic low back pain, decreased spinal mobility and restricted chest 
expansion [2]. The disease often initiates before the age of 30 and targets men two-three 
times more often than women. Large joints are also frequently involved, such as hips and 
heels. In the advanced stages, disability is mainly the result of syndesmophyte formation, 
a consequence of excessive ectopic bone formation that bridges the adjacent vertebrae 
and can eventually fuse the whole spine [4].  
1-2 Pathogenesis of AS 
1-2.1 Genetic factors 
Human leukocyte antigen (HLA)-B27 is carried by 80-95% of AS patients and the subtype 
HLA-B*2705 has the strongest correlation with AS [3]. The most validated hypotheses 
proposed to explain how HLA-B27 links to AS are arthritogenic peptide hypothesis and ER 
stress hypothesis. 
If AS were a monogenic disease associated only with HLA-B27, the disease concordance 
rate of HLA-B27 positive dizygotic twins and HLA-B27 monozygotic twins should be 
approximately the same. However, the rates of HLA-B27 positive dizygotic twins and HLA-
B27 monozygotic twins were 23% and 63% respectively [5]. This indicates that AS is 
highly heritable, but the presence of HLA-B27 alone is not causative. Genome-wide 
association studies (GWAS) also found many non-major histocompatibility complex (MHC) 
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genes to be associated with the risks of developing AS [6]. Many of them are involved in 
the regulation of immune responses suggesting these single nucleotide polymorphisms 
(SNP) might augment the auto-immunity (Table 1-1). Genes associated with radiographic 
progression include several MHC molecules, such as HLA-DRB1, HLA-B and HLA-DQA1, 
as well as other genes mainly involved in bone anabolic and catabolic pathways (Table 1-
2) [7-9]. 
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Table 1-1 Non-MHC candidate genes associated with AS and their regulatory roles in immune system. 
SNP Chromosome Position Nearby gene(s) Function  
rs6600247 1p36 25177701 RUNX3 (Runt-related 
transcription factor 3) 
Development of CD8 T cells [10] and IFN- 
producing Th17 [11].  
rs11209026 1p31 67478546 IL23R (IL-23 receptor) IL-23 receptor signalling induces IL-17 and 
IL-22 production. 
rs41299637 1q32 199144473 KIF21B (kinesin family member 
21B) 
KIF21B is involved in organelle 
transportation, such as GABAARs [12]. 
Increased KIF21B expression is associated 
with multiple sclerosis and Alzheimer’s 
disease [13]. 
rs6759298 2p15 62421949 Intergenic  
rs12186979 5p13 40560617 PTGER4 (Prostaglandin E2 
receptor subtype 4) 
PGE2/EP4 enhances Th1 differentiation and 
Th17 expansion [14]. It is also important in 
bone homeostasis (see below). 
rs30187 5q15 96150086 ERAP1 (Endoplasmic reticulum 
aminopeptidase 1) 
Peptide trimming and MHCI complex 
assembling (see below). 
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SNP Chromosome Position Nearby gene(s) Function  
rs6871626 5q33 158759370 IL12B (IL-12p40 submit) A shared subunit of pro-inflammatory 
cytokines, IL-12 and IL-23. 
rs1128905 9q34 138373660 CARD9 (caspase recruitment 
domain family, member 9) 
An adaptor protein that participates in pattern 
recognition receptor signalling [15].  
rs1860545 12p13 6317038 1. LTBR (lymphotoxin B 
receptor) 
2. TNFRSF1A (Tumour 
necrosis factor receptor 
superfamily, membrane 1. 
Also known as TNFRI) 
1. LTβR‎is‎required‎for‎lymphoid‎
organogenesis and development of 
conventional and  T cell [16]. 
2. TNFRI is ubiquitously expressed and 
mediates most TNF-induced inflammation 
[17]. 
rs9901869 17q21 42930205 TBX21 (T-Cell-Specific T-Box 
Transcription Factor T-Bet) 
A transcription factor enhances Th1 
development while suppresses Th17 
differentiation [18].  
rs2836883 21q22 39388614 Intergenic  
rs4129267 1q2 152692888 IL6R (IL-6 receptor) Required for IL-6 signalling which is 
dysregulated in a number of autoimmune 
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SNP Chromosome Position Nearby gene(s) Function  
diseases. 
rs1801274 1q23 159746369 FCGR2A (Fc receptor  IIa, 
Fc RIIA, CD32) 
A receptor of IgG Fc region of IgG1-4, 
regulates phagocytosis of immune 
complex[19].   
rs12615545 2q31 181756697 UBE2E3 (ubiquitin-conjugating 
enzyme E2E3) 
The function of UBE2E3 is unclear. Other 
ubiquitin-conjugating enzymes regulate both 
innate and adaptive immune responses [20, 
21]. 
rs4676410 2q37 241212412 GPR35 (G protein-coupled 
receptor 35) 
A tryptophan metabolite-sensing receptor 
expressed on innate immune cells [22]. 
Activation of GPR35 in human iNKT cells 
reduces IL-4 production [23].  
rs17765610 6q15 90722494 BACH2 (BTB and CNC 
homology 1, basic leucine 
zipper transcription factor 2) 
A transcriptional factor that regulates B cell 
differentiation and regulatory T cell 
development [24].  
rs1250550 10q22 80730323 ZMIZ1 (zinc finger, MIZ-type 
containing 1. Also known as 
A transcriptional co-activator that interacts 
and enhances p53 [25] and Smad3/4 [26] 
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SNP Chromosome Position Nearby gene(s) Function  
ZIMP10) transcriptional activity.  
rs11190133 10q24 101268715 NKX2-3 (NK2 homeobox 3) NKX2-3 regulates the development of 
secondary lymphoid organs [27, 28].    
rs11065898 12q24 110346958 SH2B3 (Src homology 2-B 
adaptor protein 3. Also known 
as Lnk) 
SH2B3 negatively regulates the development 
of lymphocytes and dendritic cells [29]. 
rs11624293 14q31 87558574 GPR65 (G protein-coupled 
receptor 65. Also known as T-
cell death-associated gene 8) 
It suppresses inflammatory cytokine 
expression in macrophages and inhibits 
lymphocyte and eosinophil apoptosis [30]  
imm_16_28525386 16p11 28525386 1. IL27p28 
2. SULT1A1 (sulfotransferase 
family, cytosolic, 1A, phenol-
preferring, member 1) 
1. One subunit of IL-27 which enhances Th1 
but suppresses Th2 and Th17 
differentiation and induces IL-10 
production by T cells [31]. 
2. Sulfotransferases are associated with 
different types of cancers, including 
breast, prostate cancer, lung, bladder and 
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SNP Chromosome Position Nearby gene(s) Function  
colorectal cancer [32]. 
rs2531875 17q11 23172294 NOS2 (nitric oxide synthase 2, 
inducible nitric oxide synthase) 
Converts L-arginine to nitric oxide (NO) and 
L-citrulline. NO mediates vasodilation, 
infection clearance and favours Th1 
differentiation [33]. Elevation of serum nitrite 
level has been reported in active SpA 
patients [20] 
rs35164067 19p13 10386181 TYK2 (tyrosine kinase 2) Mediates IFN, IL-12 and IL-23 pathways and 
is important in both innate and adaptive 
immune responses [34]. Deficiency of Tyk2 
protects anti-type II collagen antibody-
induced arthritis in mice [35]   
rs7282490 21q22 44440169 ICOSLG (inducible T-cell co-
stimulator ligand. Also known 
as ICOSL) 
Expressed on antigen presenting cells and 
regulates T cell differentiation. The IBD-
associated risk allele decreased cytokine 
production upon the activation of pattern-
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SNP Chromosome Position Nearby gene(s) Function  
recognition receptors [36]. 
 
Table 1-2 Non-MHC genes associated with radiographic progression [7-9] 
SNP Chromosome Position Gene Function 
rs12725747 1q42 226173544 WNT9A (wingless-type MMTV integration site 
family, member 9A) 
Inhibits chondrogenesis and 
enhances chondrocyte hypertrophy 
via decreasing Col2a1 and Sox9, 
while increasing Runx2 and Col10a1 
mRNA expression [37]. 
rs2228545 2q33 203128957 BMPR2 (bone morphogenetic protein receptor, 
type II) 
One BMP receptor subunit. (See 
below) 
rs27911 5p15 14760378 ANKH (ANKH inorganic pyrophosphate 
transport regulator) 
Exports inorganic pyrophosphate 
[38]. Loss-of-function mutation [39] 
and deficiency [40] leads to joint 
ankylosis in mice. 
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SNP Chromosome Position Gene Function 
rs928501 6q23 132317130 CTGF (connective tissue growth factor. Also 
known as CCN2) 
A matricellular protein that is required 
for forming endochondral ossification 
[41]. It also enhances M-
CSF/RANKL-mediated 
osteoclastogenesis [42] 
rs1236913 9q32 124173300 PTGS1 (prostaglandin-endoperoxide synthase 
1. Also known as prostaglandin G/H synthase 
and cyclooxygenase or COX-1) 
Converts arachidonic acid to 
prostaglandin.  
rs7909264 10q23 88679764 BMPR1A (bone morphogenetic protein 
receptor, type 1A) 
One BMP receptor subunit. (See 
below) 
rs470504 
rs470558 
11q22 102163899 MMP1 (matrix metallopeptidase 1. Also known 
as collagenase 1) 
A collagenase. The expression level 
is increased in RA synovial fluid [43]. 
Overexpressing Mmp1 reduces 
osteoblast markers in human 
periodontal ligament cells [44] 
rs833843 12q13 47650658 WNT10B (wingless-type MMTV integration site 
family, member 10B) 
Induces osteoblastogenesis and 
increases bone mass [45]. 
rs851056 17q11 39192708 SOST (sclerostin) Antagonizes Wnt signalling by 
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SNP Chromosome Position Gene Function 
binding to Wnt receptor LRP5/6 [46].  
rs8092336 18 58187063 RANK (tumour necrosis factor receptor 
superfamily, member 11a. Also known as 
TNFRSF11A) 
Receptor for RANKL on myeloid-
derived dendritic cells and activated T 
cells. Important in osteoclast 
differentiation and lymph node 
development [47].  
rs30187  
rs27044 
5q15 96150086 ERAP1 (Endoplasmic reticulum 
aminopeptidase 1) 
Peptide trimming and MHCI complex 
assembling (see below). 
rs8176785 11p15 20761862 NELL1 (NEL-like 1. Also known as ) Induces osteoblast differentiation and 
controls normal synostoses [48] 
rs1801253 10q25 115795046 ADRB1(adrenoceptor beta 1) Adrb1-/- mice had decreased femur 
bone mineral density (BMD), 
cancellous bone volume/total volume 
(BV/TV), cortical size, and cortical 
thickness [49].  
rs241453 6p21 32904204 TAP2 (transporter associated with antigen 
processing 2) 
Transports cytosolic peptides into the 
endoplasmic reticulum, to facilitate 
MHCI peptide complex formation.  
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1-2.2 Arthritogenic peptide hypothesis  
The HLA-B27 molecule is one of the type I major histocompatibility complex (MHCI), which 
presents endogenous peptides to CD8 T cells. MHCI peptide complex formation occurs in 
the endoplasmic reticulum (ER), in which peptides are trimmed by endoplasmic reticulum 
aminopeptidases 1 and 2 (ERAP1 and 2) and loaded into the peptide pocket of MHCI. 
Association between ERAP1 and AS has been reported in AS patients [50] and restricted 
to HLA-B27 positive cases [51]. The protective ERAP1 SNP, rs30187 (p.Lys528Arg) and 
rs17482078 (p.Arg725Gln) decreased peptide trimming activity [51]. Therefore, aberrant 
peptide trimming and presentation might participate in the development of AS.  
The arthritogenic peptide hypothesis suggests that HLA-B27 is particularly predisposed to 
present peptides likely derived from environmental pathogens that induce immune 
responses that cross-react with self-antigens. A number of autoantibodies have been 
found to react with proteins involved in connective tissue matrix assembling, ossification 
and bone remodelling, including glypican 3 and 4, chondromodulin 1, osteoglycin and 
osteonectin [52]. Proteoglycan (PG)-specific T cells have been reported in AS patients [53] 
and the cytotoxic T cell responses against chondrocytes could be enhanced by an 
underlying pro-inflammatory environment, such as elevated interferon (IFN)- [54]. 
Histological examination of the femoral head taken from AS patients showed that the 
accumulation of T cells in the bone marrow was significantly higher in the presence of 
remnant articular cartilage compared to the areas where articular cartilage had been 
completely resorbed. This suggests that T cells might react with proteins in the cartilage 
matrix [55].  
Many studies have been undertaken to understand the origin of arthritogenic peptides with 
no consensus emerging. Unanswered questions include how these peptides are 
processed and loaded into HLA-B27, which immune cells are the major pathological 
inflammatory cells and which self-antigens are required to substantiate this hypothesis. 
1-2.3 Misfolding of HLA-B27 induces ER stress 
Induction of ER stress by misfolded HLA-B27 is another hypothesis of the pathogenesis of 
AS [56]. The protein folding process of HLA-B27 molecules is slower and with higher mis-
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folding frequency compared to other MHCI subtypes [57]. Altered ERAP1 activity might 
affect the assembling of HLA-B27 and peptides [51]. The misfolded HLA-B27 molecules 
induce ER stress that up-regulates inflammatory responses, such as IL-23/IL-17 [57, 58]. 
However, Kenna et al., demonstrated that expression of ER stress markers in peripheral 
blood mononuclear cell and ileal biopsies were not different between AS patients and 
healthy control [59]. Neither the presence of HLA-B27, ERAP1 genotypes nor the disease 
activity were correlated with ER stress level [59]. These results suggest HLA-B27 and 
ERAP1 may regulate disease through an ER stress-independent pathway. 
The trigger of AS remains unclear; however, all genetic factors, pathogens and above 
hypotheses suggest that dysregulated inflammatory responses are related to disease 
development and progression.  
1-2.4 Interaction between host immune system and microbiome 
The frequent coexistence of gastrointestinal inflammation with AS suggests a role for the 
gut microbiome [60]. Costello et al., examined the microbial profile in terminal ileal biopsies 
using 16S rRNA gene sequencing and demonstrated significantly different microbiome 
communities in AS and healthy control. [61]. HLA-B27/h2m transgenic rats [62] and SKG 
mice [63], two SpA animal models, have reduced intestinal inflammation as well as arthritis 
when raised in a germ-free environment suggesting the gut microbiome play important 
roles in disease development. Moreover, the very distinct gut microbiome populations in 
both models prior to disease onset support that microbial signature was altered by genetic 
background [63, 64]. These results suggest that the interaction between genetic factors, 
intestinal bacteria and host immune system are critical in initiating and developing AS. 
1-3 Disease features of AS 
1-3.1 Inflammation 
Increased erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), IL-6, IL-12, 
transforming growth factor beta-β‎ (TGF-β),‎ IL-17A, and IL-23 levels in AS patients 
compared to control suggests an elevated systemic inflammatory status [65, 66]. Although 
there are no specific inflammatory markers in AS, associated polymorphisms of IL-23 
receptor suggest that IL-23, and/or its downstream cytokines, might facilitate pro-
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inflammatory pathways in AS. The increased portion of IL-23 receptor expressing cells in 
AS peripheral blood mononuclear cells, as well as the increased IL-23 receptor expression 
level on individual T cells suggests that more effector cells can respond to IL-23 in AS [67]. 
The findings that IL-17+CD4+T cells [68] or IL-17+ T cells [67] are increased in AS 
patients further support the hypothesis that IL-23 signalling is more active in AS patients. 
The most direct evidence supporting the pathological role of IL-23 was demonstrated by 
Sherlock et al., whose group showed that overexpressing IL-23 alone can induce 
enthesitis and osteoproliferation [69]. Therefore, inhibitors targeting the IL-23/IL-17 
pathway have been developed and considered for AS. 
Inflammation in the enthesis, also known as enthesitis, is a hallmark feature of SpA and 
AS. Low back pain and reduced spinal mobility are the results of local inflammation of the 
spine and SI joints. The axial skeleton contains numerous ligaments, such as those 
attached to the IVD, anterior/posterior longitudinal ligaments, ligamenta flava, ischial 
tuberosity, iliac crest and interspinous/supraspinous ligaments [70]. Peripheral entheses 
are also commonly affected in SpA, including the Achilles tendon, fascia plantaris and 
epicondylus humeri lateralis [71]. 
In addition to enthesitis, bone marrow oedema and synovitis are also inflammatory 
features of AS seen on magnetic resonance imaging (MRI) short inversion recovery 
sequence [72]. The‎concept‎of‎the‎“enthesis‎organ”‎suggests‎that‎enthesis is not only the 
interface between bone and ligament, but also the neighbouring tissues, such as 
periosteal fibrocartilage, bursa, fat, synovium and subchondral bone marrow [70]. Studies 
have shown that enthesitis, synovitis and subchondral bone marrow oedema are 
coincident in affected joints [73]. The high stress concentration in entheses increases the 
possibility of microdamage, which might result in a stimulus for immune cells from the 
synovium and bone marrow to interact directly with collagens and PG, the potential auto-
antigens highly present in the cartilage and enthesis [74, 75]. In comparison with 
mechanical-induced enthesitis, bone marrow oedemas, which implies inflammation, is 
more severe in HLA-B27 positive patients suggesting the presence of HLA-B27 
exacerbates the inflammation induced by the initial mechanical stress [76]. 
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1-3.2 Bone formation 
The most distinctive radiographic feature of spinal disease in AS is syndesmophyte 
formation at the vertebral corners as a result of excessive tissue formation [77]. Normal 
bone development processes and signalling pathways, such as intramembranous, 
endochondral and chondroidal ossification, are involved in the pathological bone formation 
in AS but are switched on temporally and/or anatomically inappropriately [73, 78, 79].  
In normal bone development, intramembranous ossification is the process in which 
mesenchymal cells differentiate directly into osteoblasts after condensation [80]. 
Intramembranous bone formation is the main mechanism of flat bone formation. 
Endochondral ossification accounts for the majority of bone formation in the body[81]. 
During endochondral ossification, mesenchymal cells differentiate into chondrocytes, 
which then produce cartilage matrices, such as type II collagen and aggrecan. 
Chondrocytes eventually undergo hypertrophy and express type X collagen and 
metalloproteinase (MMP)-13. Chondrocyte hypertrophy is accompanied by vascular 
invasion that allows the formation of marrow and brings in osteoprogenitors, which 
differentiate into osteoblasts and deposit bone matrix on the remnant cartilage scaffold 
[81].  
An alternative bone formation process involving cartilage formation is chondroidal 
ossification, in which cartilage directly transforms into bone (Figure 1.1) [78]. An in vitro 
study showed chondrocytes within cartilage explants could express osteogenic markers 
after culture, such as type I collagen, alkaline phosphatase, osteopontin, suggesting 
transformation of chondrocyte to an osteogenic cell phenotype [82]. Consequently these 
transformed chondrocytes produced osteoid in the lacunae resulting in transitions from 
cartilage to bone. Recently, Yang et al., used cell lineage tracing to demonstrate that type 
X collagen expressing cells can give rise to osteoblasts and osteocytes in vivo, further 
supporting plasticity between these cell types [83].  
Examination of 26 entheses, the common sites of excessive bone formation during either 
ageing or SpA, taken from cadavers demonstrated that spur development involves 
intramembranous, endochondral and chondroidal ossification [78]. However, the unclear 
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cartilage-bone boundary, the rarity of hypertrophic chondrocytes and vascular invasion 
suggested chondroidal ossification dominated during spur formation (Figure 1.1) if a 
cartilage template was involved [78].  
 
Figure 1.1: An example of chondroidal ossification [78].  
Benjamin et al., used Masson trichrome stain to demonstrate the chondroid bone (CB) in a 
spur at the tibial attachment of the anterior cruciate ligament. C, cartilage; CB; chondroid 
bone; BV, blood vessel; LB, lamellar bone. Scale bar: 50 mm. 
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1-3.3 Bone formation signalling  
Dysregulated bone formation-related signalling pathways are involved in pathological bone 
formation, particularly the prostaglandin E2 (PGE2), canonical wingless (Wnt) and bone 
morphogenetic protein (BMP) signalling pathways. 
1-3.3.1 PGE2 signalling    
PGE2 is converted from arachidonic acid by constitutively active cyclooxygenase (COX)-1 
and inducible COX-2 followed by PGE synthase. PGE2 exerts its effects through PGE2 
receptor subtypes 1-4 (EP1-4, Figure 1.2) [84]. EP2 and EP4 are G stimulatory (Gs) 
protein-coupled receptors that activate cyclic adenosine monophosphate (cAMP)/protein 
kinase A (PKA) or phosphatidylinositol 3-kinases (PI3K)/ protein kinase B (PKB or Akt) 
pathways. EP3 activates G inhibitory (Gi) protein and decreases cAMP production. EP1 
activates phospholipase C and regulates intracellular calcium concentration. Inhibition of 
COX decreases the production of different types of PGs, and Non-steroidal anti-
inflammatory drugs (NSAIDs) are non-selective COX inhibitors.  
PGE2 exerts anabolic roles in bone primarily through EP2 and EP4. EP2 and EP4 
agonists have been shown to improve fracture healing [85-87] and osteoporosis in 
ovariectomised rats [88, 89]. EP3 mRNA expression was undetectable in either 
osteoblastic MC3T3-E1 cell line [90] or growth plate chondrocytes [91]. Unlike EP2 and 
EP4, EP1 deficiency has been shown to improve fracture healing by increasing 
osteoblastogenesis and remodelling [92]. PGE2 is an important regulator mediating 
anabolic responses upon sensing mechanical stress. PGE2 up-regulates gap junction 
protein connexin 43 expression on osteocytes through EP2 [93]. Connexin 43 facilitates 
PGE2 release [94] hence form a positive feedback loop with PGE2. PGE2 is upregulated 
in tendon after repetitive mechanical loading suggesting it is also involved in 
mechanoregulation in tendon [95].  
In AS patients, NSAIDs have been shown to retard new syndesmophyte formation when 
given in high-dose or continuously [96, 97]. Furthermore, an SNP near PTGER4, which 
encodes PGE2 receptor subtype 4 (EP4), has been reported to be associated with AS 
suggesting that PGE2/EP4 signalling might be involved in the disease. Therefore, 
17 
 
inhibiting EP4 might be a therapeutic target for suppressing both inflammatory symptoms 
and osteoproliferation.  
 
 
Figure 1.2: PGE2 synthesis and PGE2 receptors EP1-4. [84]  
PG, prostaglandin; TXA2, thromboxane A2; IP3, inositol trisphosphate; cAMP, cyclic 
adenosine monophosphate; Gs, G stimulatory; Gi, G inhibitory 
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1-3.3.2 Wnt signalling 
The canonical Wnt signalling pathway regulates bone development (Figure 1.3) [98]. Wnt 
ligands that activate the canonical Wnt/-catenin signalling pathway include Wnt1, 3a, 7b 
and 10. These ligands bind to the frizzled receptors and low-density lipoprotein receptor 
5/6 (LRP5/6). In the absence of Wnt ligands, -catenin is phosphorylated by glycogen 
synthase kinase 3 (GSK-3 and degraded by the ubiquitin/proteasome-dependent 
pathway. Ligand binding inhibits GSK-3 hence hypophosphorylated -catenin remains 
stable and translocates to the nucleus and interacts with T cell factor/lymphoid enhancer 
binding factor (TCF/LEF). Wnt signalling is regulated by several endogenous antagonists, 
such as sclerostin and dickkopf-1 (DKK-1). Sclerostin defects are associated with high 
bone mass diseases, sclerosteosis and Van Buchem disease [99]. DKK-1 expression is 
inversely correlated with bone mineral density [100]. 
Increased serum Wnt-3 levels [101] and decreased serum sclerostin and DKK-1 levels 
[102, 103], as well as the number of sclerostin-positive osteocytes in zygapophysial joints 
of AS patients [104], suggests the activation of Wnt signalling in AS patients. Decreased 
DKK-1 and sclerostin expression is associated with the excessive tissue formation in the 
PG-induced spondylitis (PGISp) mouse model [105]. Moreover, anti-DKK-1 not only 
rescues TNF-mediated bone destruction, but also induces osteophyte formation in human 
TNF transgenic (hTNFtg) mice [102]. These support that up-regulated Wnt signalling 
pathway might be involved in excessive bone formation.   
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Figure 1.3: Canonical Wnt signalling pathway [98].  
LRP, low-density lipoprotein receptor-related protein; SOST, sclerostin; DKK, dickkopf; 
Sfrp, secreted frizzled-related‎ proteins;‎ β-cat,‎ β-catenin;‎ GSK3β,‎ glycogen‎ synthase‎
kinase-3‎β;‎TCF/LEF,‎T‎cell‎factor/lymphoid‎enhancer‎binding‎factor.‎ 
 
1-3.3.3 BMP signalling 
BMP belongs to TGF-superfamily that comprises approximately 30 members [106]. BMP 
ligand binding triggers dimerization of type I and II BMP receptors and activates the kinase 
that phosphorylates Smad 1, 5 and 8. Phosphorylated Smad 1, 5 and 8 then translocate to 
the nucleus with Smad 4 to activate gene transcription (Figure 1.4). Noggin, an 
endogenous BMP inhibitor, binds to BMPs and blocks the downstream signalling pathway 
[107]. BMP 2, 4 and 7 are differentially expressed during various stages of endochondral 
ossification and play important roles from mesenchymal condensation to bone 
development [108]. Conditional deletion of BMP2 and BMP4 controlled by Prx1 limb 
enhancer, which is expressed in limb bud mesenchyme, leads to severe limb 
developmental defects [109]. Misexpressing noggin in embryonic limb inhibits 
mesenchymal condensation and chondrocyte differentiation suggesting BMP signalling is 
required for chondrogenesis [110].  
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Figure 1.4: BMP-Smad signalling [107]  
 
Aberrant BMP signalling is associated with skeletal disease. Fibrodysplasia ossificans 
progressiva is a rare autosomal dominant disorder featured by congenital malformation of 
the great toe and heterotopic bone formation in muscle and connective tissues after birth. 
Higher expression of BMP-4 [111] and mutation in ACVR1, a BMP type I receptor are the 
underlying pathogenic mechanisms of fibrodysplasia ossificans progressiva [112].  
Evidences of BMP activation have been found in AS patients and animal models. 
Increased serum BMP-2, 4 and 7 concentrations have been reported in AS patients with 
more radiographic progression compared to those without spinal fusion [103, 113]. 
Activation of the BMP-Smad pathway also contributes to chondroproliferation and 
ankylosis in HLA-B27/h2m transgenic rats [114]. Blocking BMP signalling by 
overexpressing noggin reduced clinical scores and ankylosis in DBA mice, a spontaneous 
SpA animal model [108], suggesting BMP signalling might play important roles in joint 
ankylosis.  
21 
 
These studies suggest that PGE2/EP4, Wnt and BMP, are associated with pathological 
bone formation. However, when, how and where these signalling pathways are 
activated/dysregulated in AS is still poorly understood. 
1-4 Current therapy 
Current AS therapies primarily aim to relieve inflammatory symptoms. The first-line 
treatment includes NSAIDs and physiotherapy to reduce inflammation, pain and improve 
spinal mobility [115]. High-dose and continuous use of NSAID has been shown to retard 
new syndesmophyte formation compared to low-dose and on-demand treatment [96, 97]. 
However, some patients do not tolerate long-term use of NSAIDs due to adverse 
gastrointestinal, renal and cardiovascular side effects [116].  
TNFblockade is an alternative option. Five TNF blockers, Simponi (golimumab), 
Remicade (infliximab), Humira (adalimumab), Cimzia (certolizumab) and Enbrel 
(etanercept), have been shown to improve AS functional indices and decreased 
inflammatory lesions on MRI imaging [117-123]. When comparing different studies, a 
higher percentage of patients with shorter mean disease duration had 20% and 40% 
improvement from baseline using the Assessment of SpondyloArthritis international 
Society (ASAS) ASAS20 and ASAS40 criteria respectively and ASAS partial remission 
(Table 1-2). However, despite the rapid inflammation remission, TNF blockers only 
partially retard but do not prevent radiographic progression [124-127].  
Table 1-3: Effects of disease duration on treatment outcome  
Treatments  Mean disease 
duration  
Study 
duration 
Effects on 
Inflammation  
Ref  
Infliximab 5 mg/kg 17.2 months 16 weeks ASAS40: 61.1% 
ASAS partial 
remission: 55.6% 
[119] 
Infliximab 5 mg/kg+ 
naproxen 1000 mg daily 
1.76 years 28 weeks ASAS20: 81% [128] 
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Treatments  Mean disease 
duration  
Study 
duration 
Effects on 
Inflammation  
Ref  
ASAS40:75.2% 
ASAS partial 
remission: 61.9% 
Infliximab 5 mg/kg 7.7 years 24 weeks ASAS20: 61.2% 
ASAS40: 47% 
ASAS partial 
remission: 22.4% 
[118] 
Infliximab 5 mg/kg 16.4±8.3 years 12 weeks  ASAS20: ~70% 
ASAS partial 
remission:~22% 
[129] 
Etanercept 25mg twice/ 
week or Etanercept 50 
mg/week 
2.4 years 
(Non-radiographic 
axial SpA) 
12-24 
weeks 
12 weeks: 
ASAS20: 52.4% 
ASAS40: 33.3 % 
24 weeks: 
ASAS20: 71.2% 
ASAS40: 51.9 % 
[130] 
Etanercept 25mg 
twice/week 
2.6 years 48 weeks ASAS20: 85% 
ASAS40: 70% 
[122] 
Etanercept 25 mg 
twice/week 
10.7 years 12-96 
weeks 
12 weeks: 
ASAS20: 64% 
ASAS40: 45% 
[131, 
132] 
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Treatments  Mean disease 
duration  
Study 
duration 
Effects on 
Inflammation  
Ref  
24 weeks: 
ASAS20: 63% 
ASAS40:45% 
48 weeks: 
ASAS20: 74% 
ASAS40: 61% 
96 weeks: 
ASAS20: 74% 
ASAS40: 62% 
 
Other biological therapies, previously tested in other inflammatory diseases, have also 
been investigated for efficacy in AS; however; most do not show therapeutic effects. For 
example, anakinra, an IL-1 receptor antagonist [133]; rituximab, a B-cell depleting agent 
[134]; and tocilizumab, a monoclonal antibody targeting IL-6 receptor [135] only 
moderately improve inflammatory symptoms and functional indices. The ongoing unmet 
medical needs for an effective, if not curative treatment for AS, motivate ongoing 
investigation of different therapeutic regimens. GWAS findings as discussed in Table 1-1 
implicated several potential therapeutic targets, such as the IL-23/Th17 pathway. 
Ustekinumab neutralizes IL-12p40, a subunit of both IL-12 and IL-23, improved AS 
functional index and MRI scores [136]. Secukinumab, an anti-IL-17 monoclonal antibody, 
significantly reduced inflammatory symptoms in a small group of AS patients [137]. These 
promising results provide support for targeting other GWAS identified AS candidate genes, 
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such as ERAP1 and PTGER4, rather than adapting therapies used for other inflammatory 
therapies.  
1-5 Animal models of AS 
The difficulty of obtaining bone biopsies has limited the understanding of AS disease 
progression. Animal models provide a complementary method to study AS. An ideal 
animal model should mimic the symptoms of enthesitis, spondylitis and ankylosis. 
Additional extra-articular symptoms, such as IBD, uveitis and psoriasis are preferred as 
well. Several animal models have been used for understanding the association between 
inflammation and osteoproliferation and for testing therapeutic approaches. The benefits 
and drawbacks of each animal model are discussed below.  
1-5.1 HLA-B27/h2m transgenic rat  
Based on the strong association between HLA-B27 and AS, several lines of HLA-B27 
transgenic rat models have been developed in Lewis or Fisher rats by introducing human 
HLA-B*2705 heavy chain and the invariant chain 2-microglobulin (h2m), which stabilizes 
the confirmation of MHC [138]. The initial symptom is gastrointestinal inflammation 
followed by other inflammatory features present in SpA, such as peripheral arthritis, 
spondylitis, enthesitis and psoriasis [138]. In addition to inflammation, chondrocyte 
proliferation and syndesmophyte formation, were observed in the peripheral joints and 
spine [139]. The copy number of HLA-B27 and h2m molecules has a threshold effect on 
the susceptibility to spontaneous arthritis/spondylitis. Two rat lines that are homozygous 
for transgene loci that bear fewer than 7 copies of both HLA-B27 and h2m remained 
healthy [140]. Hemizygous expression of at least 55 copies of HLA-B27 molecule with 66 
copies of h2m [140] or 20 copies of HLA-B27 molecule with 35 copies of h2m [141] are 
required for the development of arthritis/ spondylitis. Gastrointestinal inflammation is 
absent in the latter rat line suggesting gut disease and arthritis can be independent [141]. 
However, HLA-B27/h2m transgenic rats remain healthy in a germ-free environment 
indicating that gut flora is important in priming immune responses and required for disease 
initiation [62]. 
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The disease observed in the HLA-B27/h2m transgenic rats is immune system-dependent 
and transferable by bone marrow, splenocytes and lymphoid cells [142, 143]. Although 
HLA-B27 belongs to MHCI and presumably presents antigens to CD8 T cells, depletion of 
CD8 T cells did not ameliorate the symptoms [144, 145]. On the contrary, CD4 T cells 
could transfer the disease more efficiently than CD8 T cells [142].  
Consistent with human AS pathology, the IL-23/Th17 response is also activated in arthritic 
joints [146] and inflamed gut tissues [147] of the HLA-B27/h2m transgenic rat model. The 
IL-23/Th17 pathway can be induced by a response triggered by misfolded HLA-B27 [147, 
148]. Alternatively or simultaneously, aberrant dendritic cell function might also be involved 
in enhancing IL-23/Th17 in the HLA-B27/h2m transgenic rats [149].  
Histological evidence showed that peripheral and axial entheses were affected in the HLA-
B27/h2m transgenic rats [138]. Severe inflammation, bone erosion and 
chondroproliferation were observed simultaneously at affected sites [139]. The 
chondrocyte proliferation and hypertrophy have been suggested to be the result of 
activation of the BMP/Smad pathway [114]. Anti-TNF treatment started prior to disease 
onset fully prevented the disease. Interestingly, delayed treatment decreased arthritis and 
gut inflammation but failed to inhibit the activation of BMP/Smad pathway [114, 150]. This 
result supports that early treatment is required for preventing both inflammation and 
syndesmophyte formation. 
Overall the HLA-B27/h2m transgenic rat is an important animal model of SpA, particularly 
with respect to disease mechanisms related to HLA-B27 molecule and their interaction 
with environmental factors. However, the transgene copy number-dependent outcomes 
suggest that the model may be biased as a consequence of supra-pathophysiologic 
representation of this disease pathway. Therefore, the disease progression in rats might 
be different from patients, in whom the interactions between multiple factors might be 
required to overcome other disease induction and severity thresholds. 
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1-5.2 DBA1 Mice 
Grouping adult male DBA/1 mice from different litters results in spontaneous arthritis 
particularly in the hind limbs, which is characterised by swelling and erythema in the 
interphalangeal and metatarsophalangeal joints and also enthesitis in the ankle joints 
[151]. Arthritis is accompanied with typical psoriasis symptoms, including dactylitis, nail 
deformity and dermatitis [152]. Proliferation of fibroblasts and chondrocytes leads to 
ankylosis of the ankle in this model [153].  
The proliferation of synovial tissues and infiltration of mononuclear and polymorphonuclear 
leukocytes near entheses were present in the arthritic joints [152]. Arthritis and dermatitis 
depend on IFN- and IL-17 [154, 155]. However, T cells are less important in the disease 
progression of DBA/1 mice, because neither deficiency of  norT cells altered 
disease progression [153]. The presence of neutrophils and expression of chemokine (C-
X-C motif) (CXCL) 1 and 2 and their corresponding receptors suggests the innate immune 
responses might play a role in DBA/1 mice [152, 156]. Neither etanercept, a TNF blocker, 
[157] nor dexamethasone [156] showed remarkable effects on clinical symptoms.  
This model has been used to study enthesopathy. Phosphorylation of Smads, indicating 
BMP activation, has been shown in fibroblasts as well as proliferating and hypertrophic 
chondrocytes within developing osteophytes [108]. Inhibition of BMP/Smad signalling 
pathway by overexpressing the endogenous BMP antagonist, noggin, demonstrated a 
decrease in both clinical scores and ankylosis in this model [108]. However, the absence 
of axial pathology suggests that the DBA/1 mouse model is a better model of SpA, that 
has higher predominance of peripheral disease, rather than AS in which axial disease is a 
defining feature.   
1-5.3 SKG mouse model 
The SKG mouse model carries a point mutation in the SH2 domain of Zeta-chain-
associated protein kinase 70 (ZAP-70) (ZAP-70W163C) [158]. ZAP-70 is a tyrosine kinase 
downstream of T cell receptor (TCR) signalling that regulates both positive and negative 
selection during T cell development [159]. Sakaguchi et al., demonstrated that this 
mutation altered the threshold of thymic selection thus it increased the pool of self-reactive 
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T cells, which led to spontaneous polyarthritis and bone destruction mimicking RA [158]. 
Ruutu et al., demonstrated that systemic delivery of curdlan induces not only RA-like 
arthritis, but also features resembling SpA, such as enthesitis, spondylitis, sacroiliitis, 
Crohn's like ileitis, dactylitis, unilateral uveitis, psoriasis-like skin disease and osteophyte 
formation [160].  
In a specific pathogen-free (SPF) environment, SKG mice remain arthritis-free, unless 
treated with fungal cell wall components, such as zymosan or -glucans (curdlan) [161]. 
Germ-free environment has been shown to prevent ileitis and significantly reduce the 
severity of curdlan-induced spondylitis and arthritis [63]. Increase in highly self-reactive 
CD4+ T cells induced by the ZAP-70 mutation alone is not sufficient for full disease 
development and incidence in this model as neutrophils, macrophages, IL-1, IL-6, IL-17 
and TNF-are all also involved [162, 163]. Anti-mouse IL-23 antibody and IL-17 deficiency 
both prevent the development of peripheral arthritis, spondylitis and ileitis [160]. 
Interestingly, IL-22, another cytokine down-stream of IL-23 signalling, mediates enthesitis 
but protects the intestine from inflammation [164].  
Overall, the enthesitis, gastrointestinal disease, spondylitis, uveitis and dermal 
inflammation support the SKG mouse as a good model for SpA rather than specifically AS. 
This model does add further support to the hypothesis that IL-23 signalling pathway is 
involved in the development of SpA disease. 
1-5.4 TNF overexpressing mouse 
Deletion of the AU-rich‎ elements‎ (ARE)‎ in‎ the‎ 3’-untranslated‎ region‎ (3’UTR)‎ of Tnf 
(TNF∆ARE)‎leads‎to‎increased‎TNF‎accumulation [165]. The resulting phenotype includes 
polyarthritis, bilateral sacroiliitis, mild to moderate spondylitis and Crohn's-like IBD by the 
age of 4 weeks [165-167]. The human TNF transgenic mouse model (hTNFtg) has similar 
peripheral and axial arthritis but does not present with the Crohn 's like IBD [98].  
Over-activation of TNF signalling in mesenchymal cells alone induces gastrointestinal 
symptoms and arthritis [168]. Different forms of TNF receptor (TNFR) play different roles in 
SpA. TNFRI is related to both gut disease and arthritis; however, deletion of TNFRII 
ameliorated gut disease but exacerbated the joint inflammation in the TNF∆ARE‎mouse 
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model [165]. Interestingly, T cells only contribute to the development of IBD, but not 
arthritis in these mice [165]. This may provide some explanation for variance in the 
responsiveness of these disease features to different interventions. 
Robust induction of osteophyte formation and SI joint fusion in the hTNFtg mice requires 
the additional hit of blocking DKK-1 activity [102, 166]. This suggests that the combination 
of unrestrained TNF and Wnt signalling can lead to overt excessive bone formation. 
However, it is noteworthy that overexpression of TNF induces a severe erosive phenotype 
with relatively mild osteoproliferation [102, 166, 169], suggesting that osteoproliferation is 
not a direct predominant sequela of TNF-driven inflammation. This may explain why 
monotherapy using anti-TNF drugs does not effectively prevent syndesmophyte formation.  
Reducing‎mechanical‎stress‎ameliorated‎enthesitis‎and‎osteophyte‎formation‎in‎TNF∆ARE‎
mice [169]. Since enthesitis occurs more frequently in weight-bearing joints of AS patients, 
it is possible that entheseal mechanical stress-induced micro-damages and subsequent 
repair-associated inflammation may be a trigger of disease or at least osteoproliferation in 
AS.  
Although TNF overexpression models demonstrate the interaction between TNF and Wnt 
signalling, the severe erosion and lack of consistency in spontaneous osteoproliferation 
indicate that it has limitation as a model of AS. 
1-5.5 IL-23, IL-17 or IL-22 overexpression 
A direct association between IL-23 and SpA has been demonstrated using the IL-23 
overexpression mouse model [69, 170]. Increasing systemic IL-23 levels using minicircle 
DNA dose-dependently induced enthesitis in peripheral joints, IVD and SI joints. Mice also 
develop psoriasis and aortic root inflammation, but not gastrointestinal symptoms. 
Increased bone remodelling, severe bone erosion and chondro/osteoproliferation leading 
to osteophyte formation are evident in this model.  
IL-17 and IL-22 are both downstream cytokines of IL-23; however, IL-17 overexpression 
does not lead to arthritis. On the other hand, IL-22 overexpression not only induced 
spondylitis but also up-regulated bone formation-related gene expression, but induction of 
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osteoproliferation was not confirmed [69]. These models provide strong evidence for a role 
of IL-23, likely via IL-22 induction, in peripheral arthritis, spondylitis, sacroiliitis and 
psoriasis. The symptoms of this model resemble SpA, rather than AS specifically. 
Additionally, the model is likely biased due to dependence on supra-physiologic 
expression of a single pro-inflammatory cytokine pathway. However, it does provide further 
weight to the argument that the IL-23 cytokine pathway may represent a dominant 
inflammatory process in SpA/AS and is consequently an attractive therapeutic target  
1-5.6 Proteoglycan (PG)-induced arthritis (PGIA)/spondylitis (PGISp) 
mouse model and other PG-relevant autoimmune arthritic model 
Aggrecan, the major type of proteoglycan in articular cartilage, has been suggested to 
contain autoantigens in RA and AS [53]. Aggrecan is composed of a central core protein 
(globular domains, G1, G2 and G3, and an interglobular domain) attached by hundreds of 
glycosaminoglycan side chains (chondroitin sulfate or keratan sulfate) [171]. Several 
animal models have shown that proteoglycan extracted from human cartilage or G1 
domain-specific autoimmune responses lead to peripheral and axial arthritis in the arthritis-
susceptible BALB/c mice [172-177], and full disease development requires multiple 
epitopes on G1 [171]. Since these mouse models develop similar symptoms, these models 
will be discussed together in below section. The‎ generic‎ term‎ “PG”‎ will‎ be‎ used‎ when‎
referring this mouse model as aggrecan is the major type of proteoglycans in cartilage. 
Moreover, study had shown that deglycosylated crude cartilage extracts including all types 
of proteoglycans and highly-purified aggrecan were both used in studies and induce 
disease to similar extent.  
Multiple injections of PG were required to induced peripheral arthritis and spondylitis in the 
PGISp mouse model [174]. Glant et al., showed the spondylitis followed peripheral arthritis 
and consequently progressed to ankylosis due to extensive cartilage formation bridging 
the adjacent vertebral bodies [176]. However, this study predominantly focused on the 
development of peripheral arthritis, therefore detailed analysis of disease development 
within spine has not been undertaken.  
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Some PG-related models also displayed extra-articular symptoms common in SpA. For 
example, uveitis has been reported in mice overexpressing PG-specific TCR after PG 
immunization [178], and mild intestinal inflammation has been found in recombinant 
human G1 domain (rhG1)-treated mice (Dr Tibor Glant, personal communication, 2013).  
T lymphocytes have been shown to play important roles in PG-induced arthritis. 
Transferring splenocytes from arthritic mice to Severe combined immunodeficiency SCID 
mice replicates the arthritic symptoms of donor mice, while T cell depletion abolishes the 
effects [179]. Reconstitution of G1 domain-specific TCR expressing T cells in SCID mice 
can restore the susceptibility to arthritis [175, 177]. These studies further support the 
requirement of PG-specific T cells for disease development. Among all the T cell 
populations, Th1 has been reported to dominate in PG and rhG1-induced inflammatory 
responses delivered via intraperitoneal injection; while Th17 is the predominant cell 
population mediating the inflammatory responses when mice are immunized through 
subcutaneous injection of PG/rhG1 [180-182]. The Th2 cytokine, IL-4, and regulatory T 
cells are protective in PGISp mice supporting that PG-induced autoimmune arthritis is a 
Th1/Th17-skewed disease [183-185].  
The genetic factors, excluding MHC-related genes, controlling axial disease were studied 
by crossing arthritis-susceptible BALB/c with MHC-matched arthritis-resistant DBA/2 mice 
[186]. Although spondylitis correlated with onset and severity of peripheral arthritis in 
BALB/c mice, axial disease became independent of peripheral arthritis after the F2 
generation. Linkage analysis showed that two spondylitis-related gene loci, pgis1 and 
pgis2, are linked to the axial disease in F2 mice [187]. Interestingly, combination of DBA/2-
derived pgis1 and BALB/C-derived pgis2 result in the highest disease susceptibility. The 
loci include many genes related to immune responses, such as the IL-1 family gene cluster 
that had been reported in AS [187].  
Haynes et al., demonstrated that expression of the Wnt signalling inhibitors, sclerostin and 
DKK-1, were significantly decreased in PGISp mice, suggesting that activation of Wnt 
signalling may be the causative mechanism of excessive cartilaginous tissue formation in 
the spine [105]. Therefore, down-regulation of Wnt signalling pathway inhibitors may lead 
to the activation of Wnt signalling and excessive tissue formation.  
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Although severe IVD destruction is not a common features of AS patients, the PGISp 
mouse model displays a similar disease progression to that of AS patients and has the 
advantage of being a more physiologic antigen-driven response; therefore, it is currently 
the ideal choice for studying inflammation-driven bone formation in the spine and pelvis. 
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Table 1-4: Summary of features of SpA/AS animal models 
Animal model Arthritis  Ankyloses   Pathogens Gut disease Uveitis  Psoriasis  
HLA-B27/ h2m 
transgenic rats 
Peripheral and 
axial  
Peripheral and 
axial   
Yes  Yes  No  Yes  
DBA/1 mice 
 
Peripheral  Peripheral.  Not reported Not reported Not reported Yes  
Curdlan-treated SKG 
mice 
 
Peripheral and 
axial  
Peripheral and 
axial  
Yes Yes  Yes  Yes  
TNF-overexpressing 
mouse models 
(hTNFtg and TNF∆ARE) 
 
Peripheral and 
axial  
Only reported in 
peripheral after 
anti-DKK-1 
treatment   
Not reported Only in 
TNF∆ARE 
mice  
Not reported Not reported 
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Animal model Arthritis  Ankyloses   Pathogens Gut disease Uveitis  Psoriasis  
IL-23 Overexpression Peripheral and 
axial  
Only reported in 
peripheral    
Not reported No  Not reported Yes  
PGISp and other PG 
relevant mouse models 
Peripheral and 
axial   
Peripheral and 
axial  
Not reported  rhG1-treated 
mice 
PG-TCR 
transgenic 
mice 
Not reported 
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1-6 Inflammation and bone formation 
1-6.1 Do syndesmophytes develop from inflammatory lesions?  
How inflammation links to syndesmophyte formation remains an open question. If the 
inflammation is required for bone formation, syndesmophytes should develop from 
vertebral corners that were either previously or are currently affected by inflammation. 
Furthermore, anti-inflammatory therapies should prevent syndesmophyte formation.  
The location of inflammation on MRI and syndesmophytes on X-ray provides clues about 
the temporal and spatial correlation of these disease features. The percentage of vertebral 
corners with active inflammation, resolved inflammation and without inflammation at 
baseline that developed new syndesmophyte in two years were 0%, 16-20% and 2-5% 
respectively [125, 188]. It appears that vertebral corners with resolved inflammation have 
higher incidence to develop syndesmophytes. However, more than 80% of vertebral 
corners with resolved inflammation did not progress to syndesmophytes in the study 
period suggesting that either these lesions might have a slow and/or variable radiographic 
progression rate or that regressed inflammation is not solely predictive of syndesmophyte 
formation. The sensitivity of radiography is limited and it is possible that early 
osteoproliferative events were not detected by this imaging modality. Therefore, while this 
study is suggestive, it is not conclusive regarding when, where and how syndesmophyte 
formation is initiated and progressed. The affected vertebrae only account for less than 
20% of all vertebral corners scored, and the percentage varies depending on readers [125, 
189]. More than 57% of new syndesmophytes developed at vertebral corners without MRI-
determined prior inflammation [190, 191]. Therefore it is also possible that MRI imaging 
approach was not sensitive enough to detect mild inflammation, or the imaging time points 
failed to catch acute and transient inflammatory events [192]. 
Fatty lesions on MRI T1-weighted sequence that develop more frequently either in bone 
marrow or excavated bone after resolution of inflammation is another hallmark of axial SpA 
[193-197]. However, the inflammation-fatty metaplasia-syndesmophyte formation axis was 
not found in all cases [191]. A long-term longitudinal study from the early inflammatory 
phase through to ankylosis is required for understanding the association between 
inflammation, fat metaplasia and bone formation.  
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1-6.2 Can anti-inflammatory therapies inhibit syndesmophyte 
formation? 
Direct regulation of bone formation signalling by inflammatory cytokines has been studied 
in vitro. TNFand TNF-related weak inducer of apoptosis (TWEAK) increased DKK-1 and 
sclerostin expression in synovial cells and osteoblast cell cultures [102, 198, 199]. In vivo 
studies showed anti-DKK-1 treatment resulted in osteophyte formation and SI joint fusion 
in hTNFtg mice [102, 166]. Anti-TNF treatment has been shown to decrease serum DKK-1 
level in both RA and AS patients [102, 200]. The “TNF-brake‎hypothesis” suggests that 
increased TNF during the inflammatory phase upregulates the expression of Wnt inhibitor, 
DKK-1, which suppresses bone anabolic pathway in matured lesions [201]; consequently 
TNF blockade removes this inhibition and accelerates radiographic progression. This 
hypothesis suggests that anti-TNF therapy will lead to more syndesmophyte formation. 
While anti-TNF treatment has not provided further protection against syndesmophyte 
formation compared to NSAIDs and physiotherapy over a two to four-year period, it does 
not exacerbate this process [124, 125, 127, 202-204].  
To date, most studies demonstrate a similar radiographic progression in anti-TNF and 
conventional treatments using the modified Stoke Ankylosing Spondylitis Spinal Score 
(mSASSS) score, a scoring system ranging 0-72 used to investigate structural change in 
the cervical and lumbar spine (Table 1-4). Only a few recent reports suggest that anti-TNF 
can retard the rate of radiographic progression (Table 1-5). The discrepancy in 
demonstrated effect on radiographic outcome might be due to variation in study duration 
and when treatment started. The effects of deceleration by anti-TNF might take more than 
four years to become evident [126, 205]; most of the earlier studies examining this 
treatment outcome were shorter than four years. Haroon et al., demonstrated that initiating 
anti-TNF treatment within ten years of disease onset was more efficacious at retarding 
radiographic progression than patients in which treatment was delayed for more than ten 
years [206]. Furthermore, AS patients with delayed diagnosis of longer than 8 years 
showed less improvement in inflammation markers and higher radiographic progression 
rate compared to those with an early diagnosis, even though both groups had received 
treatment for a similar time span [207]. AS patients that had syndesmophytes at baseline 
had more severe radiographic progression than those without baseline syndesmophytes 
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regardless of the treatment [202, 203, 205, 206]. The benefits of early treatment with anti-
TNF have been shown to prevent the activation of BMP/Smad signalling pathway in HLA-
B27/h2m transgenic rats [114] suggesting that timing of anti-inflammatory intervention 
has impact on the treatment outcome. 
Taken together, while inflammation may have a role in suppressing bone formation 
signalling and compromise bone repair; anti-TNF therapy does not accelerate 
syndesmophyte formation. On the contrary, early intervention prior to the initiation of 
osteoproliferation might be most beneficial for retarding/preventing radiographic 
progression.  
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Table 1-5: TNF blockers have no effects on syndesmophyte formation 
Treatments  Disease duration  Study 
duration 
Baseline mSASSS Change of mean mSASSS score Ref  
Etanercept (25 mg) 
vs  
OASIS (TNF naive) 
Etanercept: 
10±8.5 years 
OASIS:  
12±9.8 years 
2 years Etanercept:16±8.3 
OASIS: 19±20.8 
Etanercept: 0.91±2.45 
OASIS: 0.95±3.18 
(p=0.083) 
[124] 
Infliximab (5mg/kg)  
vs  
conventional 
treatment (GESPIC 
cohort) 
Infliximab: 15.5(3-
35) years 
GESPIC: 5.5(1-
10) years 
2 years Infliximab: 12.1  
 
GESPIC: 5.9  
1. All patients (p=0.92):  
Infliximab:0.7±2.8 
GESPIC: 0.4±2.7  
2. Patients with baseline 
syndesmophyte (p=0.085): 
Infliximab: 0.5±3.5 
[202] 
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Treatments  Disease duration  Study 
duration 
Baseline mSASSS Change of mean mSASSS score Ref  
GESPIC: 2.2±4.8  
3. Patients without base line 
syndesmophyte: no significant 
difference 
ASSERT (infliximab 5 
mg/kg for 48 weeks  
or Placebo for 24 
weeks infliximab 5 
mg/kg ) 
vs  
OASIS  
ASSERT: 
10.2±8.7 years 
OASIS: 9.9±8.8 
years 
2 years ASSERT: 17.7±17.9 
 
OASIS:17.5 ±15.1 
ASSERT: 1.0±3.2 
OASIS: 0.9±2.6 
(p=0.541) 
[118, 127, 
208] 
Placebo for 24 
weeks golimumab 
50 mg  
Golimumab 50 
mg: 11.0 (6.0–
18.0) years 
4 years golimumab 50 mg: 
11.7±16.4  
golimumab 100mg: 
1. Compare treatment groups  
(p=0.16):  
[203] 
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Treatments  Disease duration  Study 
duration 
Baseline mSASSS Change of mean mSASSS score Ref  
vs  
golimumab (50 mg 
and 100mg)  
With vs without 
baseline 
syndesmophyte 
Golimumab 
100mg: 9.5 (4.0–
18.0) years 
Placebo: 16.0 
(5.0–25.0) years 
13.5±18.9  
Placebo: 16.1±8.7 
 
Golimumab 50 mg:1.3±4.1 
Golimumab100mg: 1.0±5.6 
Placebo: 2.1±5.2 
2. Effects of baseline syndesmophyte 
(regardless of treatment) 
(p<0.0001): 
All patients with syndesmophyte: 
2.8±5.9 
All patients without baseline 
syndesmophyte: 0.2±1.2 
3. Among patients with baseline: 
Syndesmophyte:  
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Treatments  Disease duration  Study 
duration 
Baseline mSASSS Change of mean mSASSS score Ref  
Golimumab 50 mg:2.1±5.0 
Golimumab100mg: 2.9±6.5 
Placebo: 3.6±6.2  
4. Among patients without baseline 
syndesmophyte:  
Golimumab 50 mg:0.1±0.9 
Golimumab100mg: 0.4±1.6 
Placebo: -0.1±0.5 
Adalimumab 40 mg 
every other week vs 
OASIS 
Adalimumab: 
11.2±9.3 years 
OASIS: 11.3±8.7 
years 
2 years Adalimumab: 19.8±19.3 
OASIS: 15.8 ± 17.6 
Adalimumab: 0.8±2.6  
OASIS: 0.9±3.3 
(p=0.771) 
[204] 
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Treatments  Disease duration  Study 
duration 
Baseline mSASSS Change of mean mSASSS score Ref  
Anti-TNF (infliximab, 
etanercept, 
adalimumab) vs 
standard  
Anti-TNF: 
18.2±11.4 years 
Standard: 15 ±10 
years 
2 years Anti-TNF: 14.5±16.1 
Standard: 10±12.1 
Anti-TNF: 1.4±1.9 
Standard: 1.5±3.1 
[125] 
OASIS: Outcome Assessments in Ankylosing Spondylitis International Study 
GESPIC: GErman SPondyloarthritis Inception Cohort 
ASSERT: Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy 
 
Table 1-6: TNF blockers might retard syndesmophyte formation  
Treatments Mean disease 
duration  
Study 
duration 
Baseline mSASSS Change of mean mSASSS 
score or number of 
syndesmophytes 
Ref  
Infliximab vs Herene 
histological cohort (TNF 
Infliximab: 8 years Infliximab: 13.2±17.6 mSASSS score in 8 years: [126] 
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Treatments Mean disease 
duration  
Study 
duration 
Baseline mSASSS Change of mean mSASSS 
score or number of 
syndesmophytes 
Ref  
inhibitor naïve, but can 
take NSAID) 
15.8±8.5 years 
Herene: 20.7±5.7 
years 
Herene:14.2±13.8 1. mSASSS score 
Infliximab: 20.2±21.4 
Herene: 25.9±17.8 
(p<0.001) 
2. Mean number of 
syndesmophyte:  
Infliximab: 1.0±0.6 
Herene: 2.7±0.8 
(p=0.007) 
5 mg/kg infliximab vs 
OASIS cohort  
Infliximab: 
19.0±23.4 years 
4 years Infliximab: 11.6±15.3 
OASIS: 12.7±17.4 
Infliximab: 1.6±2.6 
OASIS:4.4 
[205] 
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Treatments Mean disease 
duration  
Study 
duration 
Baseline mSASSS Change of mean mSASSS 
score or number of 
syndesmophytes 
Ref  
OASIS: 11.7±9.3 
years 
 
TNF blockers )vs TNF 
blocker naive (NSAID 
users) 
Initiating TNF blocker 
treatment within or after 10 
years  
TNF blocker: 
16.47±11.8 years 
Naïve: 16.38±14.4 
years 
>3.9 years TNF blocker: 10.6±14.9  
Naïve: 8.2±13.8  
Patients delay >10 years had 
higher rate of mSASSS 
progression than <10 years 
(p=0.03) 
 
[206] 
44 
 
1-7 Aim of this thesis 
To date, the transition from inflammation to osteoproliferation is poorly understood, largely 
due to the limited availability of bone biopsies. What triggers osteoproliferation, the 
signalling mediators involved in osteoproliferation as well as the tipping point for activation 
of bone formation are all questions still unanswered in AS. Therefore, the aims of this 
thesis are as follow: 
Chapter 2: The temporal and sequential association between inflammation and excessive 
tissue formation will assist understanding the transition between these two phases. 
Therefore, the aim of chapter 2 is to characterise the axial disease progression from initial 
to advanced stages by an in-depth histological characterisation of the PGISp mouse 
model.  
Chapter 3: The results of Chapter 2 showed that the primary anabolic feature of the PGISp 
mouse model at 24 weeks post priming was presented as cartilaginous excessive tissue 
formation. However, whether these cartilaginous tissues could directly become mineralised 
or convert to bone was unclear. The aim of Chapter 3 is to investigate the nature of the 
excessive tissue further and whether it mineralises in a longer-term study.  
Chapter4: Previous GWAS demonstrated a strong association between AS and PTGER4, 
which encodes EP4. Since PGE2/EP4 regulates both inflammation and bone formation, 
we hypothesized that this signalling is involved in AS development. The aim of chapter 4 is 
to study whether modulating EP4 signalling is a potential therapeutic regimen for AS.  
Chapter 5: The results from Chapter 2 lead to our next hypothesis that inflammation 
results in IVD destruction, which is the prerequisite for the excessive tissue formation. 
Therefore, the aim of Chapter 5 is to test whether early and aggressive intervention with 
anti-inflammatory treatment, using a combination of high dose etanercept and 
prednisolone, can suppress inflammation and consequently reduce IVD damage and 
attenuate progression to excessive tissue formation. 
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2 Chapter 2: Inflammation is a prerequisite for osteoproliferation in 
the PGISp mouse model of ankylosing spondylitis 
2-1 Foreword  
The aim of chapter 2 is to characterise disease progression from the early to advanced 
stages in the PGISp mouse model as a model of the inflammation-osteoproliferation 
transition seen in AS. By detailed analysis of this disease progression we have provided 
some insights into following questions: 1) whether the enthesis is the site of disease 
initiation, 2) is the inflammation necessary for radiographic disease progression and 3) 
what is the nature of the pathological osseous tissue laid down. Chapter 2 has been 
prepared as a draft manuscript for submission for publication.  
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2-2 Abstract 
Objective 
Ankylosing spondylitis (AS) is an immune-mediated arthritis affecting the axial skeleton, in 
which inflammation is followed by osteoproliferation and frequently ankylosis. The 
inflammation-bone formation transition is poorly understood, and a key question is whether 
inflammation is required for osteoproliferation. This study used the proteoglycan (PG)-
induced spondylitis (PGISp) mouse model to delineate the morphological and molecular 
changes during disease progression. 
Methods 
The spine morphology of the PGISp mice was defined by a semi-quantitative histological 
scoring system evaluating inflammation, joint destruction and excessive tissue formation 
(osteoproliferation). Spinal mRNA expression was analysed by real-time PCR. Matrix 
components were identified using immunohistochemistry.  
Results 
Disease initiated with inflammation at the periphery of the intervertebral disc adjacent to 
the longitudinal ligament, reminiscent of enthesitis, and was associated with up-regulated 
Tnf and metalloproteinases. Destruction of vertebral disc, cartilage and bone were then 
observed at later time points. Advanced disease was characterised by reduced 
inflammation, excessive tissue formation and ectopic chondrocyte expansion. These 
distinct features differentiated the affected mice into early, intermediate and advanced 
disease stages. Excessive tissue formation was only observed in vertebral joints if the disc 
was destroyed as a consequence of the early inflammatory process. Excessive tissue and 
ectopic chondrocytes were enriched in cartilaginous components. Elevated spinal 
expression of cartilage markers Col2a1, Sox9 and Comp indicated upregulated 
chondrogenesis. Osteophytes were rare but more prevalent in intermediate and advanced 
disease.  
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Conclusion 
The inflammation-driven intervertebral disc (IVD) destruction in the PGISp mouse was 
prerequisite for the subsequent excessive tissue formation, which is driven by chondroidal 
ossification.  
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2-3 Introduction 
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis predominantly affecting the 
axial skeleton. The disease is characterised by inflammation at entheses, which is followed 
by an osteoproliferation phase that often leads to ankylosis of affected joints. Current 
treatments, including non-steroidal anti-inflammatory drugs (NSAID), physiotherapy and 
tumour necrosis factor (TNF)-inhibitor biologic therapies, function to relieve symptoms, and 
in the case of TNF-inhibitors reduce inflammation. 
Axial and peripheral entheses, where ligaments attach to the bone, are often affected by 
inflammation causing pain and stiffness [72]. Ankylosis in AS patients results from the 
development and fusion of syndesmophytes, defined as bony bridges growing at the 
vertebral corners. Multiple mechanisms of bone formation have been proposed to underlie 
the osteoproliferation in AS including intramembranous, endochondral, and chondroidal 
ossification [73, 209]. The causative pathological mechanisms that initiate and perpetuate 
the excessive bone formation remain unknown. There is an ongoing debate regarding 
whether inflammation is the direct trigger of this osteoproliferation. Whilst there is evidence 
that NSAIDs and TNF-inhibitors slow osteoproliferative disease, this effect is at best partial 
and ankylosis still progresses despite treatment with these agents. 
In AS patients, longitudinal magnetic resonance imaging (MRI) and radiographic imaging 
can be used to follow the disease progress, although the resolution and sensitivity are not 
sufficient to show correlations at the detailed anatomical level. Collection of serial biopsies 
from spinal lesions of AS patients would substantially aid elucidation of detailed 
mechanistic changes underlying the inflammatory responses and the mechanism of bone 
formation. A few studies have been performed on sacroiliac joint biopsies from patients 
undergoing hip replacement and in zygapophyseal joints from spinal surgeries [55, 73, 
209-211]. Such studies, although informative, are limited by sample size and location, 
coupled with being predominantly obtained from late-stage disease patients in whom the 
inflammation-osteoproliferative transition has already occurred. Disease relevant animal 
models thus present a valuable approach to elucidating mechanisms underlying disease 
progression in the axial skeleton Time course studies in spinal samples from animal 
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models present as a powerful approach to elucidate the full progression of AS, particularly 
to investigate the mechanistic link between inflammation and osteoprolifieration. 
We aimed to better delineate the disease progression in AS by studying the proteoglycan 
(PG)-induced spondylitis (PGISp) mouse model. The PGISp mouse model was chosen for 
its good recapitulation of AS clinical features including development of both inflammation 
and osteoproliferation in the spine in response to the PG epitope immune stimulus [105, 
176].  
To characterise disease progression, we performed a six-month-time time course in 
PGISp mice spanning from the onset through to advanced disease with regular sampling 
occurring throughout disease progression. We developed a novel histological scoring 
system that measured the broad array of disease features occurring during disease 
progression. We used histology, immunohistochemistry (IHC), and gene expression data 
to describe events more precisely within affected joints. Additionally, multiple matrix 
markers were assessed to identify and characterise ectopic formation of cartilage and 
bone. 
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2-4 Materials and methods 
2-4.1 Mouse model, immunization and collection 
  The PGISp model was established by treating three month old female IL-4-/- BALB/c mice 
with 2 mg of human cartilage extract (PG) together with 2 mg of dimethyl dioctadecyl 
ammoniumbromide (DDA, Sigma-Aldrich, St. Louis, MO) as described previously (Haynes 
et al [105]). IL-4 deficiency did not change disease presentation but led to higher disease 
incidence and severity over wild type BALB/c mice [183]. Therefore, IL4-/- mice were used 
in the present study. Treatment was delivered via intraperitoneal injections, administered 
in three-week intervals over a 6 week period. Age-matched naïve female IL-4 -/- BALB/c 
mice were used as controls.  
Spine samples including thoracic and lumbar vertebrae were collected 6, 8, 10, 12, 16 and 
24 weeks after the first PG injection. Between 12 to 17 mice were collected at each time 
point from each of the naïve or PGISp groups.   
2-4.2 Histology 
Spine samples from 5-10 mice at each time point from each of the naïve or PGISp group 
were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 48-72 hours followed by 
decalcification in 14% ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA, 
Sigma-Aldrich) for 3-4 weeks. The embedded spine samples were cut into 5 m serial 
sections along the sagittal plane using a standard rotary microtome. The sections were 
deparaffinised with xylene and graded ethanol and then rehydrated in tris-buffered saline 
(TBS,‎50mM‎Tris,‎150mM‎NaCl,‎pH=7.4)‎before‎staining‎with‎Mayer’s‎haematoxylin and 
eosin (H&E) or toluidine blue (0.01% toluidine blue O (Sigma) in 0.1% sodium chloride 
solution (pH = 2.0)). Sections were immersed in the stain solution for 2 minutes followed 
by an ethanol wash before being mounted in mounting medium (POCD scientific, NSW).   
Semi-Quantitative Histological Scoring   
Histological scoring criteria outlined in Table 2-1 were developed to capture the broad 
range of inflammatory, anabolic and catabolic changes that occur within the vertebral joints 
of the spine in this AS model. Representative images of scoring criteria are shown in the 
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appendix. Scoring was performed on one H&E and one toluidine blue stained section from 
each‎sample.‎Only‎samples‎with‎correct‎sagittal‎orientation‎and‎≥‎6‎IVDs‎in‎spine‎section‎
plane were included in the analysis. An average of 9 vertebral joints was scored in each 
mouse. Anterior and posterior sides of each joint were scored separately and then 
averaged to generate the final score for any given joints. Joints with a score above zero 
within any of the criteria categories were defined as affected joints and mice that had at 
least one affected IVD were defined as affected mice. PGISp mice with normal spine 
morphology were excluded from further spinal disease incidence and progression 
analyses. For the qPCR analysis this was not possible and all the mice from each group 
were analysed. The disease progression was measured by averaging scores of all 
vertebral joints within one mouse. Blinded scoring was not possible since the feature were 
quite distinct between early and late stages. 
Table 2-1: Histological score criteria  
Category  Score  Criteria  
Inflammation 0 Normal  
1 Minor infiltration of inflammatory cells at 
periphery of the joint 
2 Moderate infiltration – inflammatory pannus < 
50% joint area 
3 Marked infiltration – inflammatory pannus > 
50% joint area 
IVD destruction 0 Normal 
1 Less than 50% disc destruction 
2 More than 50% disc destruction 
3 Total disc destruction/only necrotic disc left 
Cartilage damage 0 Normal  
1 Some loss of endplate cartilage and/or growth 
plate cartilage 
2 Severe loss of endplate cartilage and some 
growth plate cartilage damage 
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3 Severe loss of endplate cartilage and severe 
growth plate cartilage damage 
Bone erosion 0 Normal 
1 One or a few small areas of resorption in 
original vertebral bone. 
2 Numerous areas of obvious focal resorption in 
original vertebral bone or several areas of 
severe destruction. 
Excess tissue 
Formation 
(excluding 
inflammatory 
infiltrate) 
0 Normal 
1 Mesenchymal cell invasion/ expansion 
2 Moderate fibrocartilage formation (<50% of the 
original disc area) 
3 Extensive fibrocartilage formation (>50% of the 
original disc area) 
Ectopic 
chondrocytes 
0 Normal 
1 Single small area 
2 Single large area 
3 Multiple areas 
2-4.3 Immunohistochemistry  
Sagittal sections (4m) were rehydrated and subjected to different antigen retrieval 
processes depending on the primary antibody. For types I and II collagen, spine sections 
were digested in pre-warmed 25% trypsin (Biocare Medical, Concord, NSW, Australia) for 
10 minutes at room temperature (RT). For type X collagen, sections were incubated in 0.1 
U/ml chondroitinase ABC (Sigma-Aldrich) in tris-acetate buffer (0.1M Tris, 30mM Acetate 
buffer, 10mM EDTA, pH6.5) for 2 hours at 37°C. No antigen retrieval was performed for 
osterix antibody. All sections were incubated in 3% H2O2 for 30 minutes at RT to inactivate 
endogenous peroxidases. Samples were further blocked in Sniper Blocking Reagent 
(Biocare Medical) for 10 minutes and 10% foetal bovine serum for 1 hour at RT. For type I   
and II collagen and osterix staining, the sections were incubated with rabbit anti-type I or II 
collagen or osterix antibodies or equivalent concentration of normal rabbit IgG for 1 hour at 
RT. For type X collagen staining, the sections were incubated with rabbit anti-type X 
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collagen anti-serum or equivalent concentration of rabbit serum overnight at 4°C. After 
washing in TBS, sections were incubated in MACH1 Horseradish peroxidase (HRP) 
polymer reagent (Biocare Medical) for 30 minutes and detected using Diaminobenzidine 
(DAB) chromogen (Biocare medical). Sections were counterstained in acidified 
haematoxylin (Sigma). Antibody, normal rabbit IgG and serum details are listed in Table 2-
2. 
Table 2-2: Antibodies for immunohistochemistry  
Antibody  Concentration  
(dilution) 
Catalogue 
number 
Company  
Rabbit anti-Type I 
collagen 
0.5 g/ml (1:2000) C7510-13 USBioLogical, 
Swanpscott, MA 
Rabbit anti-Type II 
collagen 
0.5 g/ml (1:2000) Ab34712 Abcam, 
Cambridge, UK  
Rabbit anti-Type X 
collagen antiserum 
1:8000 LSL-LB-0092 Cosmo bioco, 
Tokyo, Japan 
Rabbit anti-Osterix 0.2 g/ml (1:4000) Ab22552 Abcam, 
Cambridge, UK 
Rabbit IgG Same concentration 
as antibody 
Sc-2027 Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
Rabbit serum 1:8000 R9133 Sigma, St. Louis  
 
2-4.4 RNA extraction and quantitative real-time PCR 
The spine samples from 5-8 PGISp or 5-7 age-matched naïve female mice at each time 
point were flash-frozen in liquid nitrogen and stored at -80°C. Spine samples were 
homogenized separately in Trizol (Life Technologies, Mulgrave, Victoria, Australia), and 
RNA was extracted according to the protocol described previously [105]. Synthesis of 
cDNA was conducted using a Tetro cDNA synthesis kit (Bioline) following the 
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manufacturer’s‎ instructions.‎ Gene‎ expression‎ was‎ measured‎ by‎ SYBR‎ Green-based 
quantitative real-time reverse transcription PCR (qPCR) using the Sensimix SYBR kit and 
run on a ViiA7 Real-Time PCR System (Life Technologies). Primer sequences are listed in 
Table 2-3. PCR conditions were 10 minutes at 95˚C‎followed‎by‎50‎cycles‎of‎15‎seconds 
at‎95˚C‎and‎45‎seconds at‎60˚C.‎The‎expression‎of‎individual‎genes‎was‎normalized‎to-
actin‎and‎gene‎expression‎quantified‎using‎the‎ΔCT‎equation.‎ 
Table 2-3: Primers for real-time PCR  
Gene  Accession 
Number  
Forward Primer (5’-3’)  Reverse Primer (3’-5’)  
β-actin  NM_007393  GATTACTGCTCTGGCTC
CTAG  
GACTCATCGTACTCC
TGCTTG  
Col2a1  NM_031163  GCAGAGATGGAGAACCT
GGTA  
AGCCTTCTCGTCATA
CCCT  
Comp  NM_016685  GTCCAAGAAGAATGACG
ATCAGA  
ACAGTTGTCAGCTAC
ATTTCGT  
Mmp3  NM_010809  GATGAACGATGGACAGA
GGATG  
TGTGGAGGACTTGTA
GACTGG  
Mmp13  NM_008607  GCCATTTCATGCTTCCT
GATG  
AGACTGGTAATGGCA
TCAAGG  
Sox9 NM_011448  CGACCCATGAACGCCTT  GTCTCTTCTCGCTCT
CGTTC  
Tnfα NM_013693  AGACCCTCACACTCAGA
TCA  
TCTTTGAGATCCATG
CCGTTG  
Cartilage oligomeric matrix protein (Comp); Matrix metalloproteinase (MMP); Tumour 
necrosis factor alpha‎(Tnfα);‎Type‎II‎collagen,‎ 1 (col2a1); Sex determining region Y- box 
9 (Sox9) 
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2-4.5 Statistics  
Data was analysed by Mann-Whitney or Kruskal-Wallis tests analysis using PRISM 6 
(GraphPad Software, La Jolla, CA). P-values less than 0.05 were considered significant. 
Unsupervised analysis was conducted using the hclust function in R. Histological scores of 
affected IVD of affected mice were averaged and computed using hierarchical cluster 
analysis using Ward's method.  
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2-5 Results 
2-5.1 PGISp axial joint histopathology progresses from inflammation 
to osteoproliferation. 
To characterise axial disease progression in PGISp mice, H&E stained sections from 
spines collected across a disease time course (weeks 6, 8, 10, 12, 16 and 24 post the first 
PG injection) were semi-quantitatively scored according to the criteria outlined in Table 2-
1. These assessment criteria scored inflammation, vertebral disc destruction, bone erosion 
and excess tissue formation (mesenchymal tissue expansion or fibrocartilage formation) in 
the vertebral joints as well as ectopic chondrocyte formation. Histological scoring of these 
major disease histopathology features was used to model axial disease progression in the 
PGISp mice. All the vertebral joints and IVDs in naïve mice appeared normal throughout 
the time course and were treated as a single mouse group for statistical analysis. 
The PGISp mice exhibited early disease by 6 weeks post PG priming with 60% of mice 
having either 1 or 2 mildly affected vertebral joints (Figure 2.1A). By 8 weeks post the first 
PG injection, every PGISp mouse had at least one affected vertebra, with 50% of all 
vertebral joints affected (Figure 2.1A). The majority of joints were only mildly affected at 8 
weeks, but severe inflammation was observed in a small percentage (Figure 2.1A). 
Averaging the inflammatory score of all the vertebral joints in individual affected PGISp 
mice across the time course showed that the inflammation score peaked at 12 weeks 
(Figure 2.1B), with 18-19% of affected joints severely inflamed (Figure 2.1A). At both 10 
and 12 weeks post PG priming, the inflammation score was significantly elevated (Figure 
2.1B). There was heterogeneity in inflammation severity at any time point both between 
and within individual animals, with some vertebral joints showing no inflammation while 
others had significant joint damage (Figure 2.1B). Average inflammation severity reduced 
from 16 weeks post PG priming (Figure 2.1A). Taken together, these observations show 
that inflammation is the earliest detectable axial histopathological feature in the PGISp 
model but it is a transient disease process. 
Histopathological features of the disease reflecting destruction or tissue formation 
demonstrated a progressive or sustained disease process. Most reached maximal score at 
24 weeks post priming, much later than was observed with inflammation (Figure 2.1C-E). 
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Initiation of disc destruction (Figure 2.1C), bone erosion (Figure 2.1D), cartilage damage 
(Figure 2.1E) and excessive tissue formation (Figure 2.1F) were evident from 8 weeks 
post priming. Disc destruction and bone erosion were significantly increased from week 10 
onwards in PGISp compared to naïve mice (Figure 2.1C and D, respectively). Disc 
destruction (Figure 2.1C) and bone erosion (Figure 2.1D) peaked at the same time as 
inflammation (Figure 2.1B) but subsequently plateaued, consistent with them being 
irreparable tissue changes driven by the inflammatory processes. Excessive tissue (Figure 
2.1E) and ectopic chondrocyte formation (Figure 2.1F) increased steadily from week 10 
through to week 24. A notable feature was that in all the mice analysed, severe 
inflammation and significant excessive tissue formation did not occur simultaneously within 
the same joint, consistent with these features representing early and late stages of PGISp 
progression respectively. Another feature of late stage disease was cartilage damage, 
which was not significantly elevated compared to naïve or 6-week mice until 16 weeks 
post PG priming. This suggests that this destructive event is more likely a secondary 
consequence of other joint changes initiated by the inflammatory process. 
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Figure 2.1: PGISp mouse model disease progression.  
(A) The severity of inflammatory infiltrate is represented by the percentages of different 
scores at each time point. Axial disease progression is described by the features of; (B) 
inflammation, (C) disc destruction, (D) bone erosion, (E) cartilage damage, (F) excessive 
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tissue formation and (G) ectopic chondrocyte formation. Each point represents the 
average scores of all vertebral joints within each affected mouse at the particular time 
points (3-10 mice/time point). The results are shown as mean ± SD and analysed by a 
Kruskal-Wallis test with posttest Dunn correction. ****p<0.0001, ***p<0.001, **p<0.01, 
*p<0.05 compared to naïve.  
 
2-5.2 Inflammation drives tissue damage and disc destruction in 
PGISp mice 
Detailed histological assessment across the time course exemplified the heterogeneity of 
disease progression between different animals and even between individual vertebral 
joints, similar to that reported in AS [212]. At the 6-week time point, the earliest detected 
feature of inflammation was accumulation of inflammatory cells at the periphery of the IVD 
adjacent to the annulus fibrosus (Figure 2.2A). At 8 weeks post priming, while all mice 
were affected, within any given PGISp mouse both affected (Figure 2.2B, joints 2-4) and 
unaffected (Figure 2.2B, joints 1 and 5) vertebral joints were observed and there was a 
broad range of inflammation severity within the spine (Figure 2.2B, joints 2-4). 
Inflammatory pannus invading into the disc space drove IVD destruction, resulting in joint 
space narrowing (Figure 2.2B, space between black arrows) and was often associated 
with bone erosion (Figure 2.2C, black arrowheads). Early hyaline cartilage damage, 
including eroded surfaces defined by excavated and empty chondrocyte lacunae, was 
confined to areas exposed to inflammatory infiltrate (Figure 2.2C, yellow dash line 
represents eroded cartilage surface).  
Severe inflammation was characterised by marked infiltration of the AF by inflammatory 
cells, including polymorphonuclear cells, vascular structures and increased density of 
mixed morphology mesenchymal cells (Figure 2.2C and D). In severely inflamed joints, 
periosteal expansion and inflammatory cell invasion frequently extended along the cortical 
surface of the vertebral body, possibly following the spinal ligaments, suggesting an 
entheseal and/or periosteal pathology (Figure 2.2E, arrow). Overall the histopathology 
features suggest that the inflammatory process drives the IVD destruction and focal bone 
and cartilage damage.  
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TNFα,‎and‎MMP-3 and -13 have been implicated in AS inflammatory processes and have 
been correlated with disease activity [213-215]. Therefore, mRNA expression of these 
genes in the whole spine was measured by qPCR (Figure 2.2F). The basal level of Mmp3 
in unaffected mice was very low across the time course. PG immunisation induced a 
dramatic elevation of Mmp3 at 8 weeks and expression levels of this transcript remained 
significantly higher in PGISp mice at all later time points (Figure 2.2F). Mmp13 was 
significantly elevated at weeks 12 and 16 in PGISp spines. Tnf expression was 
significantly increased in PGISp mice at 8 and 16 weeks (Figure 2.2F). These data 
suggest that the inflammation-driven tissue remodelling molecular cascades are 
established by 8-10 weeks post immunisation and decrease in parallel with inflammation 
during the later disease stages.  
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Figure 2.2: Progression of spinal inflammation in PGISp mice. 
(A) Representative H&E stain of mild inflammation in an 8-week time point mouse. 
Inflammatory cells accumulate at the periphery of the disc (arrow), but the rest of the 
IVD appears normal. NP: nucleus pulposus; AF: annulus fibrosus; CEP: cartilaginous 
endplate; GP: cartilaginous growth plate. (B) Variable disease penetrance in a 8-week 
PGISp mouse; (1) and (5) unaffected IVDs, (2) disc destruction combined with early 
chondrocyte formation, (3) severe inflammation and disc destruction (4) moderate 
inflammation with incomplete disc destruction. (C) Magnification of the boxed area in (B) 
shows bone erosion (arrowhead) and cartilage damage. The yellow dashed line 
indicates the eroded cartilage surface. (D) Magnification of the boxed area in (B) 
demonstrates large numbers of mononuclear cells presenting in the affected joints. (E) 
inflammation expansion along the longitudinal ligament (black arrows) (F) mRNA 
expression of Mmp3, Mmp13 and Tnfin whole spine was analysed by qPCR and 
normalized to -actinBlack bars represent naïve and open bars represent PGISp mice. 
Expression levels are presented as mean ± SD. ***p<0.001, **p<0.01, *p<0.05 
compared to naïve at the same time point, Mann-Whitney test. Scale bar: (A) 300m, 
(B) 2mm, (C-D) 60m and (E) 700 m. 
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2-5.3 Disease-associated anabolic tissue pathology 
Expansion of mesenchymal cells, predominantly fibroblast- (Figure 2.3Ai,ii, arrowheads) 
and chondrocyte-like, (Figure 2.3Ai,ii, arrows) was found in the bulging residual annulus 
fibrosus of affected vertebral joints and extending along the vertebral periosteal surface. 
The chondrocyte-like cell phenotype included rounded or polygonal morphology within a 
dense predominantly basophilic extracellular matrix (ECM). In advanced disease, ectopic 
cartilaginous tissue increased as the inflammatory cell infiltrate and density of fibroblast-
like mesenchymal cells declined (Figure 2.3B, black arrows). Our results showed the 
ectopic chondrogenesis only occurred following disc destruction, with residual necrotic disk 
tissue frequently evident (Figure 2.3A-B, asterisks). Ectopic cartilage-like tissue containing 
embedded chondrocytes in columnar formation was also observed in some mice parallel 
to the vertebral periosteal surface, possibly associated with longitudinal ligament 
attachment points (Figure 2.3C, yellow arrowheads). Interestingly, inflammation was also 
noted in similar regions of other mice (Figure 2.2E, black arrows). 
To elucidate the composition of the ectopic ECM present at sites of PGISp excess tissue 
formation, the distribution of different types of collagen was analysed by IHC (Figure 2.3D). 
In unaffected vertebral joints, the annulus fibrosus and hyaline cartilage had high PG 
content (toluidine blue positive) and predominantly contained type II collagen. Type I 
collagen was weakly present in annulus fibrosus and strongly expressed by vertebral 
bone. In affected joints, the majority of the excessive tissue had a high PG content and 
contained both type II and type X collagens, verifying pathologic cartilage expansion. 
Expression of type X collagen suggested that some chondrocytes were hypertrophic. 
Consistent with previous findings [105], weak collagen type I staining seen at the periphery 
of excessive tissue areas potentially indicated progression towards a more boney 
phenotype.  
Spinal mRNA expression of cartilage matrix components and cartilage-forming regulatory 
proteins fluctuated during disease progression (Figure 2.3E). Expression of cartilage 
components Col2a1 and Sox9 were decreased at 8 and 6 weeks post priming 
respectively. From 10 weeks onwards, as inflammation peaked and excessive tissue 
formation increased, Comp was significantly elevated. Col2a1 was up-regulated at week 
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12 whilst Sox9 increased at weeks 10 and 24. This trend suggests cartilaginous matrix 
expression was increased in PGISp mice after the peak of inflammation.  
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Figure 2.3: Excessive tissue and ectopic chondrocyte formation are key features of 
advanced disease.  
(A) A 12-week mouse IVD demonstrates both early (i) and intermediate (ii) stages of 
excessive tissue formation using H&E stain. Inflammatory infiltrate (yellow arrow) 
surrounds the affected joint, while fibroblast-like cells (arrowheads) and chondrocyte-like 
cells (black arrows) are located adjacently to the residual disc (asterisks). (B) Excessive 
tissue at the periphery of the joint is greatly increased in more advanced disease (arrows). 
Representative image was taken from a 24-week mouse. (C) In addition to excess tissue 
(arrow), columnar chondrocytes expand ectopically along the cortical bone between 
affected joints (yellow arrowheads). Representative image from a 24-week mouse. (D) 
Representative images taken from 24-week mice show an unaffected IVD and affected 
joints with excessive or ectopic chondrocyte formation. Cartilaginous tissue (arrows) is 
positive for toluidine blue (PG content) and type II collagen. Type X collagen stains for 
hypertrophic chondrocytes while type I collagen delineates mature bone. (E) Spinal gene 
expression profile of cartilage markers Col2a1, Comp and Sox9 were analysed by qPCR 
and normalized to-actin Black bars represent naïve and open bars represent PGISp 
mice. Expression levels are presented as mean ± SD. ***p<0.0001, **p<0.001, *p<0.01 
compared to naïve at the same time point, Mann-Whitney test. Scale bars: (A) 300m, (i) 
and (ii) 200 m, (B) 400m, (C) 300m and (D) 100m. 
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Mature osteophyte formation, defined as aberrant bone formation adjacent to cortical bone 
(Figure 2.4A), was apparent. Osteophytes showed a variable collagen distribution with 
different areas containing collagen I-, II- or X-positive and osterix-positive cells (Figure 
2.4B). None of the weeks 6 and 8 PGISp mice developed osteophytes whilst 28.6% of 
mice at week 10 had osteophytes and the percentage increased to 71.4%, 66.7% and 
75% at weeks 12, 16 and 24, respectively. A noteworthy observation is that pathological 
tissue formation was only observed with vertebral joints that exhibited disc 
damage/destruction.  
 
Figure 2.4: New bone and osteophyte formation  
(A) Representative image of an osteophyte (arrow) in an affected joint of a 12-week PGISp 
mouse. (B) Recently formed bone tissue (arrowheads) is characterised by a transition from 
PG and type II collagen-enriched matrix to type X and type I collagen positive matrix. 
Osterix positive osteoblasts are embedded in type I collagen positive bone matrix. The 
dashed line represents the boundary between the original cortical bone and the excessive 
matrix above showing a reduction of cartilaginous matrix, toluidine blue staining and type II 
collagen accompanied with an increase of type I collagen and osterix-expressing 
osteoblasts. Arrowheads indicate cartilage tissue that is strongly positive for type I, X 
collagen and osterix but weakly for toluidine blue and type II collagen. Scale bar (A) 300 
m and (B) 100 m.  
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2-5.4 Modelling of disease   
To better model the interdependence of the different scoring criteria irrespective of time 
post-PG priming, we developed an algorithm to define different disease stages. This 
algorithm utilised an unsupervised clustering approach based purely on average affected 
vertebral joint scores across all the criteria measured. This clustering defined three 
disease stages which interestingly corresponded broadly to the time point post-priming; 
Stage 1 - early (mainly week 6-8, Figure 2.5A, left box), Stage 2 - intermediate (mainly 
weeks 10-12, Figure 2.5A, middle box) and Stage 3 - advanced (mainly weeks 16-24, 
Figure 2.5A, right box). We then further dissected the data to identify the scoring metrics 
that best delineated each stage. The scores for inflammation (Figure 2.5B), excessive 
tissue formation (Figure 2.5C) and ectopic chondrocyte formation (Figure 2.5D) strongly 
differentiated between these three groups. The early stage showed mild to moderate 
inflammation, low excessive tissue and low ectopic chondrocyte formation. The 
intermediate stage displayed severe inflammation and moderate excessive tissue and 
ectopic chondrocyte formation. The advanced stage showed decreased inflammation but 
pronounced excess tissue and ectopic chondrocyte formation.  
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Figure 2.5: Early, intermediate and late phases of disease progression are 
delineated by inflammation, excessive tissue and ectopic chondrocyte formation.  
(A) Unsupervised clustering differentiates the model into 3 stages corresponding with 
disease duration. The x-axis depicts the time points of the mice. The left box (Stage 1), 
middle (Stage 2) and right box (Stage 3) represent early, intermediate and advanced 
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stages of disease development respectively. Scores for (B) inflammation (C) excessive 
tissue formation and (D) ectopic chondrocyte formation are distinct between these 3 
groups. (E) Axial disease was initially characterised by transient inflammation that included 
vertebral joint infiltration by monocular cells, activation of tissue remodelling (MMPs) and 
pro-arthritic inflammatory pathways (TNF). Vertebral joint inflammation culminated in 
destructive changes, including destruction of the IVD, the latter of which was irreparable 
and would have considerable impact on joint biomechanics. In advanced disease, 
inflammation is decreased; however, excessive tissue and ectopic chondrocyte formation 
driven by chondroidal ossification was the predominant feature and only occurred in joints 
in which the IVD had been severely compromised. 
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2-6 Discussion 
Inflammation and syndesmophyte formation are two defining hallmarks in AS. However, 
the relationship between these features, as well as the underlying controlling factors, is 
poorly understood. Key questions that remain to be answered are whether the enthesis is 
the site of disease initiation, if the inflammation is necessary for radiographic disease 
progression, and what is the nature of the pathological osseous tissue laid down. By 
detailed analysis of disease progression in the PGISp mouse model of AS, we have 
provided some insights into these questions. 
Entheses, categorized as fibrocartilaginous or fibrous entheses, are traditionally just seen 
as focal interfaces between ligament and bone. The spine possesses abundant ligaments 
including IVD, anterior/posterior longitudinal ligaments, ligamenta flava, and 
interspinous/supraspinous ligaments [70]. It is hypothesized that entheses are prone to 
microdamage, which allows immune cells from the synovium and bone marrow to enter 
entheses and interact with the potential autoantigen in the entheses, such as aggrecan 
[74, 75]. The presence of HLA-B27 molecules might augment the immune responses [76]. 
Peripheral enthesitis has been described in other spondyloarthropathy (SpA) animal 
models, such as HLA-B27 transgenic rats [138],‎ TNFΔARE‎mice‎ [168], grouped DBA/1 
male mice [154] and curdlan-treated SKG mice [160]. Disease in the PGISp mouse model 
is induced by autoimmunity against PG [216]; therefore, we examined whether entheses 
are the primary sites of disease initiation.  
The detailed histology analysis in the present study revealed that the inflammatory 
invasion started at the periphery of the annulus fibrosus. Further inflammatory infiltrate and 
ectopic chondrocytes were also shown to expand along the inter-IVD cortical bone 
surfaces. Although we do not show definitive proof of entheses in these regions, it is well 
established that the longitudinal spinal ligaments has frequent attachment points in this 
area [217, 218]. Spinal enthesitis presenting as pannus formation outside of the annulus 
fibrosus was also reported in HLA-B27 transgenic rats [138] and curdlan-treated SKG mice 
[160]. Our result supports the hypothesis that enthesial inflammation is the primary site 
and mode of disease in the PGISp mouse model.  
72 
 
The limited effects of anti-TNF therapies on radiographic progression raise the question as 
to whether inflammation is required for osteoproliferation in AS. Our detailed histological 
examination suggests inflammation, excessive tissue formation and ectopic chondrocyte 
formation typify early, intermediate and late disease stages, respectively. We 
demonstrated that early mesenchymal expansion initiated before resolution of 
inflammation; however, severe inflammation was never found simultaneously with severe 
excessive tissue formation within the same joint supporting sequential rather than parallel 
progression of these disease features. Therefore, our model predicts that inflammatory 
lesions are likely to have decreased, if not resolved, in the later disease stages typified by 
syndesmophyte formation. This prediction is supported by MRI studies in AS patients that 
have shown: 1) new syndesmophytes are seen more frequently in vertebral corners with 
resolved inflammation [188]; 2) 68% of syndesmophytes developed from vertebral corners 
without active inflammation during the 2-year observation period [190]. Although, some 
consideration needs to be given to the sensitivity limits of MRI for detecting mild 
inflammation [192].  
Excessive tissue formation only occurred at vertebral joints in which the IVD itself had 
been destroyed. This implies that the sequence of PGISp disease progression is initiation 
with inflammation leading to disc destruction. IVD spaces are generally preserved in the 
presence of syndesmophytes in AS patients [219] although there is some degree of disc 
degeneration degree which is higher than that seen in non-rheumatoid disease control 
patients and the severity was associated with duration of disease and BASFI index [220]. 
However, the results were unable to delineate the cause-effect relationship between disc 
degeneration and syndesmophyte formation. The association between disc degeneration 
and syndesmophyte formation had not been studied yet.  
Axial disease presented in the PGISp model is distinct from other rheumatoid arthritis 
rodent models. Severe cartilage destruction, proteoglycan depletion and bone erosion 
observed in collagen-induced arthritis (CIA) [221], collagen type II antibody-induced 
arthritis (CAIA) [222] and antigen-induced arthritis models [222] are often accompanied 
with inflammatory pannus. Nevertheless, inflammation in PGISp mice was not the leading 
cause of endplate cartilage damage even after inflammation destroyed the disc. Other 
typical features of rheumatoid arthritis mouse models were not evident in the PGISp mice, 
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such as bone marrow oedema in the rat adjuvant-induced arthritis (AIA) [223] or 
angiogenesis in the CIA mouse model [224]. These might be due to different animal 
models, but it also suggests that the mechanisms behind peripheral arthritis might not be 
applicable to spondylitis.   
In the PGISp mouse model, as inflammation decreases, excessive tissue formation 
commences with ectopic chondrocyte formation occurring late. Such a progression 
concurs‎ with‎ the‎ “TNF-brake‎ hypothesis”‎ previously‎ proposed‎ by‎ Maksymowych‎ et al., 
[225] which suggests high level of inflammatory TNF inhibits osteoproliferation and this 
inhibition is eased as TNF levels drop with resolution of inflammation .This also matches 
data from rheumatoid arthritis models in which osteoblast function was inhibited in the 
presence of inflammation [226] and induced after inflammation resolution [227].  
Enthesitis and osteoproliferation have also been reported in DBA/1 mice [153], HLA-
B27/h2m transgenic rats [139] and curdlan-treated SKG mice [160]. However, the 
relationship between the processes is not well-defined. In the DBA/1 mouse model of 
ankylosing enthesitis, chondrocyte proliferation was the leading cause of ankle ankylosis 
[152, 153]. The entheseal proliferation and inflammatory infiltrate were minor in this model 
and treatment with glucocorticoids [156], but not etanercept [157], did ameliorate 
inflammation somewhat but had no effect on the ankylosis. In a longitudinal study in HLA-
B27/h2m transgenic rats, osteoproliferation was found external to the joint space 
separate from inflammatory infiltrates [139]. However, osteoproliferation and inflammation 
in HLA-B27/h2m transgenic rats were presented simultaneously suggesting distinct but 
parallel processes. Interestingly, although blocking TNF signalling before or after onset 
prevented or reduced arthritis respectively, chondroproliferation and its activation of 
relevant bone morphogenetic protein (BMP) signalling were only prevented by early 
treatment [114]. In the SKG mouse model, bone formation and erosion were shown to be 
adjacent to inflammation although it is not clear if there is a progression through these 
different features as a detailed longitudinal study was not undertaken [160]. So while 
evidences from other animal models are not clear as to the relationship between 
inflammation and osteoproliferation, our extensive analysis in the PGISp model clearly 
supports a direct progression from inflammation to bone formation. 
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Direct connection of the ectopic chondrocytes and cartilage to the vertebral cartilaginous 
endplate or growth plate was not a consistent histological feature, indicating that these 
ectopic tissues were not due to expansion of existing cartilage structures. The annulus 
fibrosus [228], periosteum [229] and ligament [230] all contain potential chondrocyte 
precursors. Therefore, it is possible the chondrogenesis is initiated from progenitors 
located within these disease-affected tissues without direct involvement of pre-existing 
cartilage. Several features of the excessive tissue in the advanced disease resembled 
endochondral ossification, such as cartilage formation and chondrocyte hypertrophy. 
Hypertrophic chondrocytes have been shown to be able to transform directly into 
osteoblasts and osteocytes subsequently becoming embedded in mature bone [83]. Bleil 
et al., recently demonstrated zygapophyseal joint ankylosis was caused by direct 
transformation from cartilage to bone without chondrocyte hypertrophy [79]. The direct 
transformation/ossification from chondrocytes represents chondroidal ossification [73] and 
might be the primary mechanism of excessive tissue formation in this model. Examples of 
mature osteophyte were rare in this study but more evident in later disease stages. This 
finding suggests the transformation of cartilage to bone in PGISp mice is a slow process 
modelling the prolonged window between disease onset and radiographic change in AS 
patients [2].  
Our results suggest that if inflammation is not treated early enough to prevent irreparable 
structural damage, further chondro/osteoproliferation at that location may progress even if 
the inflammatory process is resolved. The benefits of early intervention regarding both 
spondylitis and radiographic progression have been demonstrated with different 
treatments. After treatment with infliximab for 16 weeks, 61% of patients with short disease 
duration (13.4 months) had 40% improvement from baseline [119] whilst only 47% of 
patients with long disease duration (7.7 years) reached the same criteria after 24 weeks of 
treatment [118]. Delaying TNF intervention therapy for 10 years was related to faster 
radiographic progression compared to those who started treatment within 10 years of 
disease onset [206]. The benefit of early intervention was also seen using NSAID. AS 
patients with short disease duration (< 5 years) had less radiographic progression [96] 
compared to those with long disease duration (11.9 years) [97] following chronic high dose 
NSAIDs treatment. These studies suggest that anti-inflammatory therapies exert better 
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clinical outcome in early AS/SpA patients compared to those whose disease is 
established.  
Taken together, our study indicates inflammation leads to IVD destruction in the PGISp 
mouse AS model. The latter is a prerequisite for induction of excessive tissue formation, 
with chondroidal ossification rather than endochondral or intramembranous ossification 
appearing to be the most likely mechanism. This study emphasises the advisability of 
intervening early in AS patients with more potent anti-inflammatory therapeutic regimens in 
order to prevent inflammation-induced destructive changes and consequently reduce the 
frequency of osteoproliferative events. 
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3 Chapter 3: Extended time course to characterise ongoing disease 
progression in the PGISp mouse model 
3-1 Aim of the long-time course study  
In Chapter 2, we demonstrated that the PGISp mouse model mimics many features in AS 
patients and is a good model for studying the inflammation-osteoproliferation transition. 
Our results suggested that the mechanism behind the pathologic bone formation is 
chondroidal ossification. However, a number of issues require further clarification. Firstly, 
at 24 weeks post the first PG injection, the extensive excessive tissues that were observed 
in effected joints were mainly composed of cartilaginous matrix but we had no data 
regarding the mineralisation status of this matrix. Consequently it was not clear whether 
this cartilaginous matrix directly mineralised or, if given sufficient time, progressed to bone 
formation by a more traditional endochondral ossification-like mechanism. Secondly, the 
histology analysis only examined excessive tissue formation in two dimensional (2D) 
sagittal planes; whether osteophytes developed in other planes was not investigated. We 
therefore investigated whether the excessive tissue transformed into bone or mineralised 
cartilage over a longer time course of the disease using 3D computed tomography (CT). 
CT and histological observations were correlated. In this extended time course study, we 
anticipated formation of osteophytes either due to bony conversion or direct mineralisation 
of the cartilaginous excessive tissue evident at 24 weeks. 
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3-2 Materials and methods  
3-2.1 Animal experiments 
The induction of axial disease was performed as described in the manuscript presented in 
Chapter 2. A total of 15 PGISp mice were collected at 38-43 weeks after the first injection. 
Three age-matched DDA alone-treated and 4 age-matched naïve mice were used as 
control. Skeletons were fixed in 4% paraformaldehyde for 48 hours. The skeletons were 
either processed immediately for histological analysis only or stored in PBS for 1-2 weeks 
before ex vivo CT imaging. A subset of the CT-imaged samples was subsequently 
processed for histology. Mouse numbers in each outcome assay stream are specified in 
Table 3-1.  
Table 3-1: Mouse numbers applied to the specific analysis streams 
 Histological 
analysis 
only 
CT analysis only Both Histological 
and CT analysis 
PGISp 6 6 3 
Naïve or DDA alone-
treated IL-4-/- mice 
1 4 2 
3-2.2 CT imaging 
The bone micro-architecture of the spine was imaged ex vivo using a Siemens Inveon 
positron emission tomography–computed tomography (PET-CT) multimodality system 
(Siemens Medical Solutions Inc., Knoxville, TN, USA). Parameters were as follows: 360° 
rotation, 360 projections, 80kV voltage, 270μA current, and effective pixel size 27.5μm. All 
images were reconstructed with a down sampling factor of 1, using Cobra Reconstruction 
software (Exxim 6.3.39 Computing Corp). 
3-2.3 Histology  
Skeletons were decalcified, processed and sectioned at 4 m as described in the 
manuscript presented in Chapter 2. After deparaffinization and rehydration, sections were 
78 
 
processed for basic histology staining. For H&E staining sections were immersed in 
Mayer’s‎haematoxylin‎(Sigma-Aldrich) for 2 minutes, rinsed in tap water for 5 minutes and 
then stained with eosin (Sigma-Aldrich) for 1.5 minutes. Safranin O/fast green staining was 
performed to study PG content in the cartilage. In brief, rehydrated sections were stained 
with‎ Mayer’s‎ haematoxylin‎ (Sigma-Aldrich) for 2 minutes, rinsed with tap water for 5 
minutes followed by staining with 0.02% fast green (Sigma-Aldrich) in 1% acetic acid for 
one minute, rinsed in 1%acetic acid/70%EtOH for 30 seconds and 1% safranin O for 10 
minutes. Protocol for toluidine blue stain was the same as described in Chapter 2. After 
H&E, toluidine blue and safranin O/fast green staining, the sections were quickly rinsed in 
95% and 100% ethanol followed xylene and mounted in mounting medium (COPD). 
3-2.4  Immunohistochemistry 
Type I and II collagen and isotype control staining protocol was the same as described in 
the manuscript presented in Chapter 2. 
3-3 Results 
3-3.1 3D assessment of spine morphology demonstrated osteophyte 
orientation varied with spine localisation 
To characterise pathologic mineralisation in 3D, axial skeletons were scanned by CT. 
Seven out of 9 mice scanned using CT had severe disc space narrowing and presented a 
variety of CT spinal abnormalities suggestive of abnormal bone formation or mineralisation 
features compared to healthy controls. These two outlier mice had no evident IVD space 
narrowing or bone erosion, implying they only had mild disease, an anticipated outcome 
given disease variability demonstrated in Chapter 2. Most of the abnormalities, which are 
outlined in detail within this Chapter, were simultaneously observed in all but two mice.  
In anteroposterior (Figure 3.1A, green, red and blue arrows) and transverse (Figure 3.1B-
D) views of CT scans, hyperdense projections, presumably osteophytes, extended 
perpendicularly from the vertebral bodies were more common in the middle and lower 
thoracic spine compared to other regions. These osteophytes were not visible in most 
lateral views (Figure 3.1E). Hyperdense CT signal with structural appearance resembling 
ectopic bone (defined as abnormal bone formation including psuedo bone marrow cavity 
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and trabecular structures) was an additional minor feature observed in the lower thoracic 
spine of the PGISp mice (Figure 3.1A and D, arrowheads). None of these features were 
observed in the middle-lower thoracic spine of control mice (Figure 3.1F-J). 
 
Figure 3.1: Osteophyte formation of the PGISp mice.  
CT images were taken from the eighth to eleventh thoracic vertebrae (T5-T8) of a PGISp 
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mouse at time point 40 weeks on (A) anteroposterior view, (B-D) transverse sections on 
(B) T5, (C) T6 (D) T7, and (E) lateral view. Osteophytes are indicated by green, red and 
blue arrows while red arrowheads indicate ectopic bone formation. (F-J) The thoracic 
spine (T5-T8) of an age-matched healthy control IL-4-/- mouse on (F) anteroposterior view, 
transverse sections of (G) T5, (H) T6, (I) T7 and (J) lateral view. 
 
Most PGISp mice at 38-43 weeks developed extensive ectopic hyperdense mineralised 
structures that led to ragged bone surface and widening of almost every vertebral body 
above the third thoracic vertebrae (T3) (Figure 3.2). These mineralised structures in the 
upper thoracic spine were seen on the lateral view (Figure 3.2A-D, red arrows) but not the 
anteroposterior view (Figure 3.2E). Histological assessment of the same samples, with 
section orientation and depth matching CT plane and depth, showed that these 
mineralised structures lacked safranin O positive PG (Figure 3.2C, red arrows) but 
contained high type I collagen positive matrix (Figure 3.2D, red arrows). These 
observations indicate that these are areas of ectopic mature bone formation. Most excess 
tissues at the edge of vertebrae contained high PG (Figure 3.2C, asterisk) in the absence 
of type I collagen (Figure 3.2D, asterisk). Some PG-expressing chondrocytes were 
embedded in the matrix that contained very low PG (Figure 3.2C, black arrowheads) and 
no type I collagen expression (Figure 3.2D, black arrowheads). Compared to diseased 
mice, healthy aged IL-4-/- mice showed a normal appearance with a smooth cortical 
surface of vertebral bodies (Figure 3.2F, G).  
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Figure 3.2: Ectopic bone formation of the PGISp mice.  
(A-G) Extensive ectopic bone formation in T1-T2 of a PGISp mouse at 40 weeks. (A) 
Lateral view of CT image, (B) H&E stain (C) safranin O/fast green stain and (D) type I 
collagen IHC. (E) Anteroposterior view in matched joints. Ectopic bone formation is shown 
between red arrows. Asterisk indicates high PG cartilaginous excessive tissues. Arrow 
heads indicates transition from cartilage to chondroidal bone. (F-G) CT images of upper 
thoracic spine of an age-matched healthy control on (F) lateral and (G) anteroposterior 
view. Scale bar in (B-D): 200 m. An: anterior. Po: posterior. 
 
3-3.2 Fusion of vertebral bodies and zygapophysial joints in PGISp 
mice 
Hyperdense CT signal was observed between vertebral bodies and zygapophysial joints 
indicating bony fusion. Complete vertebral fusion was only seen in the cervical spine 
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(Figure 3.3A-D). The cartilaginous endplate and growth plate remnants had fused with the 
adjacent trabeculae (Figure 3.3 A-E, yellow arrows). To demonstrate that transformation 
from cartilaginous excessive tissue (Figure 3.3F-H, black arrows and asterisks) to 
chondroidal bone (Figure 3.3F-H, black arrowheads) have occurred, serial sections were 
stained for both cartilaginous and bone components. Cartilaginous excessive tissue 
expressed high PG and, variable type II collagen without type I collagen (Figure 3.3F-H, 
black arrows and asteriks). In contrast, the periphery of excessive tissue near the fused 
IVD (Figure 3.3C, boxed area and Figure 3.3 F, black arrow heads) gradually lost PG 
(Figure 3.3F, black arrowhead) and type II collagen (Figure 3.3G, black arrowhead) but 
showed increased type I collagen expression indicating chondroidal bone formation rather 
than merely fibrocartilage or PG-depleted cartilage (Figure 3.3H, black arrowhead).  
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Figure 3.3: Vertebral body fusion in the PGISp mice.  
Fusion of the second and third cervical vertebrae (C2-C3) on the (A) CT image, (B) H&E 
stain, (C) toluidine blue stain, (D) type II collagen and (E) type I collagen IHC. Yellow 
arrows indicate remnant endplate and growth plate. The black box delineates the region 
shown in (F-H). Black arrows identify areas with high PG and high type II collagen content 
but no type I collagen; while asterisks represent cartilaginous tissues with high PG content 
but low type II collagen expression. Black arrowheads show chondroidal bone that 
expresses type I collagen but low cartilaginous matrix. Scale bar: (B-E) 200 m, (F-H) 50 
m. 
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The zygapophysial joints have been suggested to be involved in AS [79, 231]. In the 
PGISp mouse model, a number of zygapophysial joints were fused (Figure 3.4, red 
arrows). Zygapophysial joint fusion did not show preference in a specific spinal region and 
the presence of other abnormal mineralisation features in the vertebral bodies was not 
predictive for zygapophysial joint fusion.  
 
Figure 3.4: Zygapophysial joint fusion in the PGISp mice.  
CT images on (A) lateral view of the spine from the 10th thoracic vertebrae (T10) to the 
second lumbar vertebrae (L2). Yellow arrowheads identify unfused zygapophysial joints 
showing clear hypodense CT signal gaps between joints. Red arrows highlight fused joints. 
(B) Transversal sections of one unfused (yellow arrowhead) and one fused zygapophysial 
joint (red arrow) (C) An affected vertebrae with both zygapophysial joints unfused. (D) CT 
images of T11-L1 of an age-matched healthy control on lateral view. 
3-3.3 Mineralisation of the cartilaginous excessive tissue 
To study whether excessive tissues progressed to bone or mineralised cartilage, CT 
images were aligned with the H&E, safranin O/fast green and type I collagen stained 
sections from the same bones. This approach facilitated delineation of exactly which 
tissues were mineralised in the CT images.  
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The normal IVD structure had a hypodense gap between adjacent vertebral bodies with 
CT imaging (Figure 3.5A) with the mineralised endplate (yellow arrowheads) and 
subchondral bone separated by un-mineralised growth plates (red arrows). Histology 
analysis confirmed the IVD had normal appearance on H&E stain (Figure 3.5B) with 
expected PG distribution in safranin O/fast green staining (Figure 3.5C) and expected type 
I collagen distribution by IHC (Figure 3.5D). 
 
Figure 3.5: An unaffected IVD on lateral view  
(A) CT image, (B) H&E stain (C) safranin O/fast green stain and (D) type I collagen of an 
unaffected IVD (between L1-L2) of a PGISp mouse at 40 weeks. Yellow arrowheads 
indicate cartilage endplates. Red arrows indicate growth plates. Scale bar: (B-D) 200 m. 
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Histological analysis in PGISP mice showed that the excess tissue in mice collected 38-43 
weeks after priming had cartilage morphology similar to that observed at 24 weeks and 
reported in Chapter 2. These excessive tissue deposits were often associated with foci of 
hyperdense mineralised material on CT images (Figure 3.6, yellow arrowheads). These 
mineralised foci were always observed near the vertebral corners without direct connection 
with cortical bone. The excessive tissues in the same region of the CT foci were abundant 
in chondrocytes (Figure 3.6B, yellow arrowhead) and PG-enriched matrix (Figure 3.6C, 
yellow arrowhead) but not type I collagen positive matrix (Figure 3.6D, yellow arrowhead). 
The hyperdense CT signal of these mineralised foci (Figure 3.7A, yellow arrowhead) could 
also be associated with necrotic disc that still contained remnant annulus fibrosus (Figure 
3.7B, yellow arrowheads) and low PG (Figure 3.7C, yellow arrowheads). These 
mineralised foci were frequently observed along the spine; however, it required histology 
analysis to differentiate whether theses hyperdense CT signals located in excessive tissue 
or necrotic disc.  
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Figure 3.6: Calcification of cartilaginous excessive tissue.  
(A) CT image of an IVD between T8 and T9 taken from a PGISp mouse at 40-weeks. (B) 
H&E stain, (C) safranin O/fast green stain and (D) type I collagen of matched IVD on CT 
images. Yellow arrowhead indicates mineralised tissue. Scale bar: (B-D) 200 m.  
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Figure 3.7: Mineralisation of necrotic disc remnants.  
(A) CT image of an IVD between T11-T12 taken from a PGISp mouse at 40-weeks. Yellow 
arrowhead indicates the mineralised disc. (B) H&E stain, (C) safranin O /fast green stain 
and (D) type I collagen of the same IVD. Scale bar: (B-D) 200 m. 
 
3-3.4 Mineralisation in IVD of PGISp mice 
Extremely hyperdense CT signal areas were frequently noted filling in the IVD space, 
particularly in the lumbar or lower thoracic spine (Figure 8A, asterisks). All mice had 1-3 
IVDs showing this feature in the present study. Histology analysis demonstrated that these 
mineralised areas had cracked, acellular appearance (Figure 3.8B, asterisks), lacked PG 
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(Figure 8C, asterisks) and type I collagen expression (Figure 3.8D, asterisks), again 
suggestive of necrotic disk remnants. However, not all regions of observed necrotic tissue 
(Figure 3.9, red asterisks) and cartilaginous excessive tissue (Figure 3.9, blue arrow) were 
mineralised based on CT imaging (Figure 3.9A and B).  
 
Figure 3.8: Mineral deposition within the IVD space.  
(A) CT image of an IVD between T12-T13 taken from a PGISp mouse at 40-weeks. 
Asterisk indicates the mineralised tissue. (B) H&E stain, (C) safranin O/fast green stain 
and (D) type I collagen IHC in serial sections of matched IVD. Scale bar in (B-D): 200 m. 
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Figure 3.9: Unmineralised excessive tissue formation and necrotic tissue.  
CT image of an IVD between T3-T4 taken from a PGISp mouse at 40-week time point. (B) 
H&E stain, (C) safranin O/fast green stain and (D) type I collagen IHC in serial sections of 
the matched IVD. Red asterisk indicate necrotic disc while blue arrows indicate non-
mineralised excessive tissue that can only be seen by histology but not on CT scan. Scale 
bar: (B-D) 200 m. 
 
3-3.5 Mapping aberrant mineralisation in the PGISp mice  
The most frequency and anatomical distribution of each of the CT exposed features was 
mapped schematically in Figure 3.10. Features distributed all along the spine were 
mineralised foci and zygapophysial joint fusion. Extensive ectopic bone developed on 
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almost every cervical and upper thoracic spine above T3, while osteophyte formation was 
the major feature in the lower thoracic spine. Ectopic bone and osteophytes were found in 
other regions but at lower frequency, and ectopic bone formation in the lower thoracic 
spine was usually smaller than the ones on the upper spine. Mineral deposition was only 
present in 1-3 IVD in the lower thoracic or lumbar spine in any of the mice analysed. 
 
Figure 3.10: Distribution of abnormal bone formation, mineralisation and fusion 
features in the PGISp mice. 
The schematic map is based on CT images of PGISp mice at 38-43 weeks post priming 
(n=7). Solid lines are features of abnormal bone formation; dashed lines are features of 
mineralisation related to IVD or cartilage; dotted lines are fusion of joints. C: cervical 
vertebrae. T: thoracic vertebrae. L: lumbar vertebrae. 
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3-4 Discussion 
In the studies reported in Chapter 3 we anticipated observation of more osteophyte 
formation in mice with advanced disease compared to Chapter 2. The observations 
reported in this chapter showed that extensive mineralisation of this tissue did occur in the 
PGISp model but progression required an extended time period. This kinetics of 
progression is not dissimilar to AS which often has a protracted disease course [232]. Our 
assessment of mineralised pathological tissue patterns presented as several interesting 
abnormal bone formation and mineralisation features: osteophyte, ectopic bone, 
mineralised cartilage, mineralised IVD, vertebral body and zygapophysial joint fusion.  
There are some discrepancies between abnormal bone formation in the PGISp mice and 
the syndesmophytes in AS patients. The syndesmophytes of AS patients usually develop 
from the vertebral corners at an angle <45° and bridge two adjacent vertebral bodies [233]. 
However, the osteophytes of PGISp mice grew outwards, and mineralised cartilage in the 
excessive tissue did not bridge the vertebral bodies. The upright/bipedal posture, 
anatomical structure and less severe IVD destruction in AS patients might generate 
distinct mechanical stress that acts upon the spine thus explaining the variation is 
osteophyte distribution and angle. Despite this variation, in comparison with other SpA 
animal models, discussed in detail within the literature review presented in Chapter 1, the 
PGISp mouse model still presents the most similar spinal disease progression to that seen 
in AS patients. Due to this we believe it is currently the best animal model to study how 
inflammation and structural damage can induce excessive bone formation and abnormal 
mineralisation in the spine.  
In the end of Chapter 2, we hypothesized that inflammation-derived IVD destruction 
altered mechanical stress, which subsequently activated osteoproliferation and result in 
excessive tissue formation. In the extended time course study, all the abnormal bone 
formation features were observed in affected vertebral joints. Hence, the current results 
still support our earlier conclusion. The various morphologies, orientation and frequency of 
these features might be due to the crouched/quadrapedal posture of mice that results in 
differences in the mechanical stresses acting on the spine.  
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Biomechanical stress has been suggested to be associated with enthesitis in the 
TNF∆ARE‎mice‎and‎osteophyte‎ formation‎in‎the‎CAIA‎ [169]. In the 24-week time course 
study, we suggested that entheses at the interface between anterior/posterior longitudinal 
ligaments were potentially involved in the disease initiation and development. If this was 
the case, it would be expected that most ectopic bone and osteophytes formation would 
develop near the anterior/posterior longitudinal ligament entheses. However, much of the 
osteoproliferation was not associated with entheses in the present study. CT quantitative 
analyses in AS patients also showed that syndesmophytes developing from vertebral rim 
were not always related to anterior/posterior longitudinal ligament entheses [219]. These 
suggest that entheseal mechanical stress might not be the only factor influencing this 
pathologic outcome. 
It is noteworthy that the abnormal bone formation reported in this Chapter occurred in a 
similar anatomical position to the severe inflammatory infiltrates (Chapter 2, Figure 2.2E) 
and ectopic chondrocytes (Chapter 2, Figure 2.3C) that were observed adjacent to the 
periosteum during 24-week time course study. The ectopic chondrocytes that presented 
with a columnar distribution similar to growth plate might contribute to abnormal bone 
formation through an endochondral ossification-like mechanism. The periosteal layer is 
known to contain osteo-chondroprogenitors that can give rise to either cartilage or bone 
under the right conditions through either endochondral or intramembranous bone 
formation [234, 235]. Filling the sub-periosteal space with osteo- or chondro-inducing 
biomaterials led to in situ woven bone or cartilage formation without supplementing with 
growth factors or additional progenitor cells [236]. Periosteal osteophyte formation is also a 
feature of a number of arthritic animal models, such as the AIA, CIA rat models [237], 
K/BxN serum transfer mouse model [238, 239] and the DBA mouse model of SpA [240]. 
Therefore, periosteal reaction might contribute to ectopic chondrocyte and abnormal bone 
formation in inflammatory arthritis. Further histological analyses across the time course or 
dynamic histomorphometric analysis are required to determine when and how the ectopic 
bone develops.  
Large anterior osteophytes have been known to result in dysphagia and airway 
obstruction in AS patients [241, 242].The cervical and upper thoracic vertebrae in this 
model presented the least well preserved vertebral structure with CT images showing 
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extensive erosion, ectopic bone, excessive tissue formation and vertebrae fusion (Figure 
3.2 and 3.3). Ectopic bone and the adjacent excessive tissues appeared like a 
disorganized expansion of the vertebral body and cartilaginous endplate/growth plate.  
The histology showed that the majority of excessive tissues near the vertebral corners in 
the PGISp mouse model retained cartilage morphology even 43 weeks post priming. 
Mineralisation assessed through CT images suggests the presence of mineralised 
cartilage. Direct transformation from chondrocytes to osteoblasts have been suggested in 
normal bone development [83] as well as in the zygapophyseal joints of AS patients [79]. 
Direct Von kossa and masson trichrome stains would be more appropriate for studying 
calcification than H&E stain in the present study. Un-decalcified sections stained with a 
nonaqueous alcoholic eosin staining method [243] or alizarin red [244] under polarizing 
microscopy compared with an immediate section stained with H&E and collagen type II 
would help to clarify the components of calcified materials.  
IVD calcification has been reported in fused spines in AS [245]. Altered calcium 
metabolism has been suggested to contribute to AS, such as increased carbonic 
anhydrase I (CAI), an enzyme that catalyses the hydration of CO2 to H2CO3 and 
participates in calcium deposition [246, 247]. ANK a transmembrane protein that exports 
inorganic pyrophosphate (ppi) and maintains the ratio of intracellular to extracellular ppi 
concentration [248], is increased in the progressive ankylosis (ank) model [7]. Loss-of-
function mutation [249] and deletion of ank [40] leads to ectopic bone formation in almost 
all joints in these mice. The spinal disease of the ank/ank mouse model, which carries 
loss-function mutant ank, displayed mineral deposition and chondrocyte hypertrophy in the 
annulus fibrosus by the age of 8 weeks, and complete ankylosis by syndesmophytes by 18 
weeks [39]. However, the important element of AS, inflammation, is absent in the disease 
development of ank/ank mouse model. Therefore, altered calcium metabolism might be a 
second co-trigger of osteoproliferation. IVD calcification is found in other degeneration-
related disc pathological conditions, such as disc degeneration disease [250] and 
protruding disc [251], suggesting it might be associated with mechanical force. 
The location and orientation of osteophytes might explain why these features were rarely 
seen in the earlier 24-week time course histological analysis, even though these mice 
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might have already developed osteophytes. The tissue collected in the previous 24-week 
time course experiment only included middle-lower thoracic to upper lumbar spine. 
Histological analysis focused on the sagittal sections (equivalent to the lateral view of CT 
images) of the centre of the vertebral bodies. This method allows clear images of most IVD 
and is ideal for scoring other features that are not region- and orientation- specific. 
However, most osteophytes were small and developed on the lateral sides of the vertebral 
bodies, implying our histological analysis was not ideal for detecting osteophytes. 
However, the upper thoracic spine, on which osteophytes should be clearly seen on the 
lateral view as Figure 3, was not collected in the 24-week time course experiment. 
Therefore, the better protocol to study abnormal bone formation in PGISp mice is to 
perform in vivo CT assessment during the time course to follow the progression of 
osteophyte/ectopic bone formation, and before processing for histological analysis and 
decide the orientation of histological analysis based on CT images. 
Taken together, we have demonstrated a number of interesting anabolic features in the 
PGISp mouse model, including abnormal cartilage and bone formation features. We 
suggested that chondroidal ossification is involved in the excessive tissue formation near 
destroyed IVDs. Also the excessive cartilaginous tissue reported at 24 weeks might be 
transformed into mineralised cartilage over an extended time period. Finally, periosteal 
reactions might be involved in the formation of multiple osteophytes and ectopic bones 
adjacent to periosteum in the middle of the vertebral bodies. 
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4 Chapter 4: Targeting PTGER4 as a potential therapeutic approach in 
AS 
4-1 Introduction  
A single nucleotide polymorphism (SNP) near PTGER4 that increases the risk of AS was 
identified in genome-wide association studies (GWAS) [51]. PTGER4 encodes one of the 
prostaglandin E2 (PGE2) receptors, PGE2 receptor subtype 4 (EP4). EP2 and EP4 are the 
predominant PGE2 receptors expressed on cells involved in inflammation and bone 
formation [252, 253] which are features of early and late stage AS respectively.  
PGE2 has both pro-inflammatory and anti-inflammatory roles. Its immune suppressive 
functions include down-regulating IFN- production by macrophages [254] and inhibiting 
neutrophil recruitment to the inflamed intestine [255]. Recent studies indicate that the pro-
inflammatory roles of this PGE2/EP2/EP4 axis are mainly through regulating Th1/Th17 cell 
development. Low PGE2 levels assist Th1 differentiation while high levels induce Th17 
differentiation [256]. This pathway also facilitates IL-23-induced Th17 development by 
increasing IL-23 expression in dendritic cells [256, 257]. Misoprostol, a non-selective EP 
agonist, has been shown to augment arthritic symptoms in the CAIA model and increase 
inflammatory cytokine expression in the joints, including IL-23, IL-17, TNF and IL-6 [258]. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are non-selective cyclooxygenase 
inhibitors that exert anti-inflammatory effects by blocking PGE2 synthesis (Figure 1.2). 
NSAIDs have been recommended as the first-line therapy for AS [115].  
The pro-inflammatory role of PGE2/EP4 signalling in arthritis has been studied using gene 
knockout mice, as well as with receptor subtype-specific agonists and antagonists. EP4 
deficiency [259] and ER-886046, an EP4 antagonist [260], significantly reduced the 
incidence and severity of CAIA. Prophylactic or therapeutic administration of ER-819762, 
an EP4 antagonist,  improved the clinical symptoms of both CIA and glucose-6-phosphate 
isomerase (GPI)-induced arthritis mouse model [257]. Prophylactic administration of CJ-
023,423 [261] or therapeutic administration of MF498 [262], two different EP4 antagonists, 
significantly reduced paw swelling in the AIA rat model. The above studies suggest that 
EP4 specific antagonists might be potential anti-inflammatory therapies in arthritis.  
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PGE2 also plays important roles in bone anabolism mainly through EP2 and EP4. PGE2 
mediates mechanical stress-induced bone formation [263]. It up-regulates the expression 
and activity of a gap junction protein, connexion 43, which is a gap junctional intercellular 
communication subunit important in bone cell communication [264]. Deficiency of EP4 led 
to decreased osteoblastogenesis and osteopenia [88, 265], whereas ONO-4819, an EP4 
agonist, enhanced osteoblasts differentiation in animal models [266]. Administration of 
ONO-AE1-329, an EP4-specific agonist, increased osteoblast number and bone mineral 
density in ovariectomised rats [88]. CP-734432, another EP4 agonist, rescued the delayed 
and impaired fracture healing responses in COX-2 knockout mice [87]. In opposition to its 
anabolic effects, PGE2 also exerts catabolic effects through up-regulating 
osteoclastogenesis via EP2 and EP4 [267, 268]. An in vitro study showed that PGE2 
induced osteoclast differentiation in mouse bone marrow culture; the effect was partially 
replicated by ONO-AE1-259 (EP2 agonist) or ONO-AE1-329 (EP4 agonists) alone, while 
the synergistic effect of these two agonists was similar to PGE2 stimulation [269]. PGE2 
signalling regulates both anabolic and catabolic process during bone remodelling, while 
the overall effects of activation of PGE2 signalling dominates anabolic effects in vivo [266, 
270]. 
NSAIDs have been reported to retard radiographic progression at high dose [96] and 
continuous use [97, 271] compared to low dose treatment. However, it is not yet clear 
whether decreased radiographic progression is due to inhibition of bone formation or 
through inhibiting inflammation. 
Based on the following rationale, we hypothesized that activation of PGE2/EP4 signalling 
plays an important role in AS pathogenesis: 1) PTGER4 is associated with AS, 2) AS is 
characterised by both inflammation and ectopic osteoproliferation and 3) PGE2/EP2/EP4 
signalling can promote both inflammation and bone formation. Therefore, the PGE2/EP4 
axis may be a common signalling pathway that drives both inflammation and the 
progression to osteoproliferation in AS. To test this hypothesis, PGISp mice were treated 
with an EP4 antagonist, ONO-AE2-227, or an agonist, ONO-AE1-329. To differentiate the 
effects of EP4 from other EPs, indomethacin, a non-selective COX inhibitor which blocks 
PGE2 production and the downstream EP1-4 signalling, was used in the study as a 
positive control. Intermittent human parathyroid hormone peptide 1-34 (hPTH 1-34) 
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treatment served as a positive control for bone anabolism as it has been shown to 
increase osteoblastogenesis [272]. Treatment with hPTH 1-34 had been widely used in 
clinic to prevent fracture and improve bone mineral density (BMD) [273-275]. We predicted 
that ONO-AE2-227 and indomethacin would reduce the severity of inflammation and 
excessive tissue formation whereas ONO-AE1-329 would exacerbate disease.   
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4-2 Materials and methods 
4-2.1 Treatment  
The disease induction was conducted as previously detailed in Chapter 2. PGISp mice 
were treated with ONO-AE1-329 (EP4 agonist), ONO-AE2-227 (EP4 antagonist) [276] or 
an NSAID, indomethacin, from the first day of immunisation until the day of sacrifice (3-6 
mice/group). Table 4-1 lists the details of all treatments and the suppliers of the reagents. 
All mice were sacrificed 16-20 weeks after the commencement of treatments (Figure 
4.1A). IL-4-/- mice used in this study were sourced form an internal breeding colony housed 
within The University of Queensland Biological Resource Facilities (Princess Alexandra 
Hospital (PAH) and Australian Institute for Bioengineering and Nanotechnology (AIBN) 
facilities). All experiments were approved by the University of Queensland animal ethics 
committee. 
Table 4-1: Details of treatments 
Drug  Function  Administration  Company  Dosage  Mouse 
number 
ONO-AE1-
329 
EP4 agonist Subcutaneous 
injection 
Ono 
Pharmaceutical, 
Osaka, Japan 
0.05 
mg/kg/daily  
5 
0.1 
mg/kg/daily 
5 
0.3 
mg/kg/daily 
6 
ONO-AE2-
227 
EP4 
antagonist 
Oral gavage Ono 
Pharmaceutical,  
10 
mg/kg/daily 
5 
20 
mg/kg/daily 
5 
30 
mg/kg/daily 
5 
hPTH 1-34 Bone 
anabolism  
Subcutaneous 
injection 
H-4835, 
Bachem 
30 
g/kg/daily, 
4 
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Bubendorf, 
Switzerland  
5 
days/week,  
indomethacin  Non-steroid 
inflammatory 
drug 
Oral gavage I8280, Sigma-
Aldrich  
2 
mg/kg/daily 
3 
4-2.2 Clinical peripheral arthritis score 
  The peripheral arthritis symptoms of all mice were scored daily. Score criteria are 
described in Table 4-2. The peripheral scores are presented as the sum of four paws in 
the following contents and figures.  
Table 4-2 Clinical score 
Hind limbs  
0 Normal  
0.5 Minimal inflammation in only ankle or toe 
1 Mild swelling of ankle and tarsal 
1.5 Inflammation spreads to metatarsal and toes 
2 Severe inflammation from ankle to toes 
3 Very severe inflammation from ankle to toes 
Front paws  
0 Normal  
0.5 Mild swelling in carpal or digits 
1 Moderate swelling in the carpal and digits 
2 Severe swelling in the carpal and digits 
4-2.3 Histology and scoring regimen  
The histology and scoring regimens used were the same as in Chapter 2 of this thesis.  
4-2.4 Serum cytokine measurement  
Anaesthesia was induced by methoxyflurane before cardiac bleeding at sacrifice. Blood 
samples were clotted at room temperature (RT) for 3 hours and centrifuged at 1000xg for 
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15 minutes. Serum was separated and stored at -80℃. Serum IL-17 was measured using 
the IL-17A‎ ELISA‎ MAX™‎ Deluxe set (BioLegend) following‎ the‎ manufacturer’s‎
instructions. Ninety-six well plates were coated with anti-IL-17 antibody overnight at 4℃ 
and washed in wash buffer (phosphate-Buffered Saline (PBS) plus 0.05% Tween-20, 
pH7.4). After blocking with assay diluent at RT for one hours, five-fold diluted serum 
samples and standards were added to the wells and incubated at RT for two hours. All 
samples and standards were assayed in triplicate. Plates were washed and incubated with 
biotinylated detection antibody at RT for one hour. Avidin-horseradish peroxidase (HRP) 
was added and incubated at RT for 30 minutes followed by a 20 minutes reaction in 3, 
3′,5,5′-Tetramethylbenzidine substrate in dark. The enzymatic reaction was stopped with 
2N H2SO4 and the absorbance at 450 and 540 nm was read using a Synergy MX multi-
mode reader (Biotek). A standard curve, which included the following concentrations; 
1000, 500, 250, 125, 62.5, 31.25, 15.6 and 0 pg/ml, was used to calculate serum IL-17 
concentration.  
Serum CRP level was measured using mouse CRP ELISA DuoSet kit (R&D system, 
DY1829, Minneapolis, Minn., USA). The procedure was the similar to the IL-17 ELISA with 
the following modifications. The serum samples were diluted 15,000 fold in 10% fetal 
bovine serum (FBS). Plates were coated with capture antibody overnight at RT. The 
incubation time with biotinylated detection antibody and avidin-HRP was 2 hours and 20 
minutes respectively. The standard curve included the following concentrations 1500, 750, 
375, 187.5, 93.75, 46.88, 23.44 and 0 pg/ml. 
4-2.5 Bone mineral density  
BMD and bone mineral content (BMC) were measured by dual x-ray absorptiometry (DXA) 
using a Piximus (GE Lunar) before and after treatment in vivo. Mice were anesthetized by 
intraperitoneal injection of zoletil (40mg/kg) and xylazine (10mg/kg) before the scan.  
4-2.6 CT image  
Pelvis bone micro-architecture was imaged using the same acquisition protocol described 
in Chapter 3. All ONO-AE1-329 and ONO-AE2-227-treated PGISp mice were imaged in 
vivo. Anaesthesia was induced using 1-2% of isoflurane with air-oxygen mixture. The 
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imaging system was non-functional at the scheduled collection time points for DDA alone-
treated mice, hPTH 1-34 and indomethacin-treated PGISp mice. Consequently, no CT 
data was obtained for indomethacin and hPTH 1-34-treated mice but skeletons of DDA-
treated mice were fixed in 4% paraformaldehyde and stored in 70% ethanol until the 
Inveon had been repaired.  
4-2.7 Statistical analyses 
The statistical significance of data was analysed by Mann-Whitney analysis. P value less 
than 0.05 was considered as a significant difference. The relationship between two data 
outputs were determined by Spearman correlation. Above statistical analyses were 
performed using PRISM 6 (GraphPad Software, La Jolla, CA). 
Sample size calculation was conducted using a power calculator 
(http://powerandsamplesize.com/) with a significance  of 0.05 and power of 1-=0.8. 
Sample size was calculated through 2-tailed distribution calculation.  
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4-3 Results  
4-3.1 Peripheral arthritis was not affected by either an EP4 agonist or 
antagonist  
Clinical arthritic scores were used to monitor the development of peripheral arthritis. There 
was large score variation within groups, which greatly restricted the ability to perform 
meaningful between-group comparisons with the current sample size. All dosages of 
ONO-AE1-329 (an EP4 agonist) and 10 and 20 mg/kg/day of ONO-AE2-227 (an EP4 
antagonist) resulted in a non-significant trend of reduction in the mean arthritic scores up 
to 70 days post commencing treatment (Figure 4.1B and C). The small peak of peripheral 
arthritis scores in the ONO-AE2-227 30 mg/kg/day group between days 30-35 days after 
treatment was due to extremely severe disease progression in two mice (Figure 4.1C). 
The onset of peripheral arthritis, defined as the day when any paw reached score one, was 
delayed in the ONO-AE1-329 0.1 mg/kg/day group (Figure 4.1D). Overall, the EP4 agonist 
and antagonist did not have a significant impact on peripheral arthritis.  
The hPTH 1-34 and indomethacin-treated mice all developed arthritis. However, the 
symptoms were scored by multiple technicians during a period when I was absent. The 
data exhibited significant scorer-dependent variation (data not shown). Therefore, the data 
was deemed to be compromised and was not included in Figure 4.1. 
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Figure 4.1: Peripheral arthritis was not affected by either an EP4 agonist or 
antagonist.  
(A) PGISp mice were treated with ONO-AE1-329 (EP4 agonist), ONO-AE2-227 (EP4 
antagonist), hPTH 1-34 or indomethacin (IND) for 16 weeks from the first day of 
immunisation. (B-C) Peripheral disease development was scored visually and presented 
by the sum arthritic scores of all four paws across the time course. Agonist and antagonist-
treated mice are compared with the same untreated mouse cohort but presented in (B) 
and (C) respectively. (D) The graph shows the disease onset after the first immunisation. 
Disease onset was determined as the first day of peripheral arthritis score of 1 reached. 
Data is presented by mean ± SD. The statistical significance of data was analysed by 
Mann-Whitney analysis. *p<0.05 compared to untreated PGISp mice. 
 
4-3.2 Targeting EP4 did not affect axial disease development 
The percentage of affected IVD (Figure 4.2A) and inflammation scores (Figure 4.2B) were 
not significantly different across all the treatment groups. Only a trend of reduced bone 
erosion (Figure 4.2C), disc destruction (Figure 4.2D), cartilage damage (Figure 4.2E), and 
excessive tissue formation (Figure 4.2F), and ectopic chondrocyte formation (Figure 4.2G,) 
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was noted in the group treated with low dose 0.05mg/kg/day of EP4 agonist. Overall, there 
were no significant effects on histological scores compared to untreated PGISp mice 
(Table 4-3, end of Chapter 4). 
 
Figure 4.2: Targeting EP4 did not affect axial disease development. 
Spinal disease progression scored on H&E staining are described by (A) the percentage of 
affected vertebral joints in one mouse. Histological features include (B) inflammation, (C) 
disc destruction, (D) bone erosion, (E) cartilage damage, (F) excessive tissue formation 
and (G) ectopic chondrocyte formation. Data was presented by mean ± SD. Each point 
represents the average scores of all vertebral joints of one mouse.  
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4-3.3 Targeting EP4 did not affect serum inflammatory markers  
PGE2/EP4 is known to regulate inflammation and Th17 cell in vivo [256]; hence serum IL-
17 and CRP levels were used to examine the systemic inflammatory status. Serum IL-17 
(Figure 4.3A, p=0.4430) and CRP levels (Figure 4.3B, p=0.4134) did not differ between 
any of the treatment groups. Final peripheral inflammation scores did not correlate with 
either serum IL-17 (r=-0.0075, p=0.6703) or CRP (r=-0.1118, p=0.4596). Histological 
scores did not correlate with serum IL-17 (r=0.1840, p=0.2784) CRP (r=-0.0066, 
p=0.9688).  
 
Figure 4.3: Targeting EP4 did not affect serum inflammatory markers.  
(A) Serum IL-17 and (B) CRP level of DDA control and PGISp mice treated with ONO-
AE1-329 (agonist), ONO-AE2-227 (antagonist), hPTH 1-34 and indomethacin for 16 
weeks were was measured using ELISA. Data is presented by mean ± SD. The statistical 
significance of data was analysed by Mann-Whitney analysis. Difference is considered 
significant when p<0.05. 
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4-3.4 Targeting EP4did not have significant influence on bone  
To examine whether ONO-AE1-329 and ONO-AE2-227 exerted any systemic effects on 
bone, we measured BMD and BMC using DEXA before treatment and upon experiment 
completion and calculated the percent change in bone paramters. The BMD and BMC 
were increased in the lower spine, pelvis and femur of the PGIS mice treated with hPTH 1-
34 (Figure 4.4 B-G). However, among all the treatments tested, only ONO-AE1-329 at 0.1 
mg/kg/day and indomethacin increased pelvis BMC when compared to untreated PGISp 
mice (Figure 4.4 E); while all other treatments had no significant effects on BMD and BMC 
(Table 4-3). 
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Figure 4.4: Targeting EP4 did not affect BMD and BMC of lower spine, pelvis and 
femur.  
The BMD and BMC of PGISp mice treated with ONO-AE1-329 (EP4 agonist), ONO-AE2-
227 (EP4 antagonist), hPTH 1-34 and indomethacin were measured using dual x-ray 
absorptiometry. (A) The representative image of region analysed. Boxed area indicated the 
(1) lower spine, (2) pelvis and (3) femur. Lower spine was determined by drawing a 
rectangle (99x30 pixels) parallel to the spine and above the pelvis. The pelvis analysed 
included sacrum and both iliac bones. The left femur was analysed in a rectangle with 
length from knee joint to iliac bone and width by 16 pixels. All mice were scanned before 
and after 16-week treatment, and the increase or decrease of (B) lower spine BMD, (C) 
lower spine BMC, (D) pelvic BMD, (E) pelvic BMC, (F) femoral BMD and (G) femoral BMC 
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was presented as the percentage change compared to baseline. Data is presented by 
mean ± SD. **p<0.01, *p<0.05 compared to untreated PGISp mice, with statistically 
significant differences determined using a Mann-Whitney test. 
 
Bone morphometry was also analysed by CT to determine the localized effects of the EP4 
agonist and antagonist on bone. The total bone volume of the 6 th lumbar vertebrae, 
including calcified cartilage, cortical bone and trabecular bone (Figure 4.5A), was not 
different between all treatments (Figure 4.5B, Table 4-3). Since disease severity might 
affect bone structure, the vertebral body analysed was grouped according to IVD 
destruction, which was defined by the presence (Figure 4.5C, yellow arrowheads) or 
absence of space between the adjacent vertebrae (Figure 4.5D, red arrowheads). The 
severity of IVD destruction did not affect the mineralised tissue volume (Figure 4.5E). The 
cortical bone thickness was neither changed by treatments (Figure 4.5F, Table 4-3) nor by 
IVD destruction (Figure 4.5G, Table 4-4, end of Chapter 4). There were no CT images of 
hPTH 1-34-treated mice due to technical problems. 
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Figure 4.5: Mineralised tissue volume and cortical bone thickness were not changed 
by an EP4 agonist and antagonist.  
(A) The cortical bone, trabecular bone and mineralised cartilage were analysed with CT 
images. The region of interest (green area) in the 6th lumbar vertebrae is shown in three 
planes. Left to right: transversal, lateral and anteroposterior. (B) The total mineralised 
tissue volumes are not different between all treatments. The space between two vertebral 
bodies indicates the severity of destruction: (C) The presence of inter-vertebrae spaces 
(yellow arrowheads) and (D) the absence of space indicates destroyed IVD (red 
arrowheads). (E) The mice are further grouped according to the severity of IVD 
destruction. N: no significant narrowing of IVD space as the example in (C); D: complete 
destroyed IVD as the example in (D). The features above IVD/below IVD were indicated as 
label. The cortical bone thickness was measured and grouped according to (F) the 
treatments and (G) the severity of IVD destruction. Data is presented by mean ±  SD. The 
statistical significance of data was analysed by Mann-Whitney analysis. Difference is 
considered significant when p<0.05. 
111 
 
4-4 Discussion   
4-4.1 EP4 in inflammation- peripheral, axial inflammation and serum 
inflammatory markers 
We hypothesized that blocking EP4 using the antagonist would reduce inflammation. 
However, only daily administration of a low dose of ONO-AE2-227 showed a non-
significant trend towards delaying peripheral disease onset compared to untreated mice. 
Power calculations suggested a sample size of 55, 59 and 263 mice was required for 10 
20 and 30 mg/kg/day respectively indicating the anti-inflammatory effects are not 
significant (Table 4-5, end of Chapter 4).  
It is known that Th17 are the primary cell type mediating EP4-related auto-immune 
diseases. EP4 antagonists have demonstrated promising inflammatory suppression in 
contact hypersensitivity, autoimmune encephalomyelitis (EAE) and CIA mouse models, 
which are all known as Th17-mediated diseases [256, 257, 277]. EP4 has disparate roles 
in Th17 development. PGE2 inhibits naïve T cells from differentiating into Th17 in vitro, 
while it enhances IL-17 production by matured Th17 and memory T cells [278, 279]. The 
dual effects have been proved using the EAE mouse model, in which EP4 enhances 
inflammation in the immunization phase, but then switches to anti-inflammation during the 
elicitation phase [277]. Therefore, administration of EP4 antagonist at different stages 
might lead to different therapeutic outcomes. However, the PG immunisation route in the 
present study was intraperitoneal injection, which was recently reported to induce arthritis 
predominately through Th1 instead of Th17 cells [280]. This may explain why blocking EP4 
signalling showed no effects in this experiment.   
Overall, the effects on peripheral arthritis in this study do not support our original 
hypothesis. The time point in our study had already passed the peak of axial inflammation; 
therefore, whether EP4 blockade had any effects on the initial spinal inflammatory phase 
cannot be determined from the current study. An earlier time point with larger group 
numbers would be required to further establish whether EP4 plays a role in PGISp axial 
inflammation.   
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4-4.2 EP4 in bone formation 
We hypothesized that excessive tissue formation in the PGISp mice is associated with 
PGE2/EP4 signalling. Therefore, an EP4 agonist was expected to increase bone formation 
while antagonists would suppress bone formation. Subcutaneous injection of hPTH 1-34 
increased spinal BMD and BMC suggesting that PGISp mice can respond to systemically 
administered bone anabolic agents. However, neither an EP4 agonist nor EP4 antagonist 
significantly effected BMD, BMC, mineralised tissue volume and cortical bone thickness of 
PGISp mice. 
EP4 agonists have been suggested to increase bone anabolism; however, it might be 
dependent on the animal strains and disease models. EP4 agonists have been proven to 
rescue osteoporosis in ovariectomised rats [89, 270, 281]. However, the anabolic effect of 
ONO-AE1-329 on vertebrae was insignificant and only augmented by osteopontin 
deficiency [282]. Subcutaneous injection of ONO-4819, an EP4 agonist, enhanced ectopic 
bone formation in collagen pellets containing recombinant BMP-2 implanted on mouse 
back; however, systemic delivery of EP4 agonist in the same study did not affect tibial 
BMD and BMC [283]. Similarly, L-161982, an EP4 antagonist, inhibited PGE2-induced 
increase of tibial cancellous bone area without affecting basal level [284]. The above 
studies suggest that EP4 signalling might only be effective in certain pathological 
conditions, such as osteoporosis. Moreover, EP4 signalling might need to work 
synergistically with other signalling pathways to exert an effect on bone, such as BMP-2.  
Another factor causing the discrepancy between our study and the literature might be the 
region analysed. Most regions analysed in the literature are the tibia, femur and lumbar 
spine; however, different bone regions might have different sensitivity to EP4 signalling. 
Lumbar and caudal vertebrae have different responses to ONO-4819, an EP4 agonist, 
even though they are both parts of the axial skeleton [270]. Similarly, administration of 
ONO-AE1-329 at 30g/kg three times daily for three weeks significantly increased bone 
volume to total volume ratio in femora but not vertebrae [282]. Moreover, CP-734432, an 
EP4 agonist, has been shown to increase osteoid volume and osteogenesis marker 
expression without changing cancellous bone volume [89]. Taken together, the effects of 
EP4 agonists and antagonists appear to be skeletal site-dependent. 
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4-4.3 EP4 in excessive tissue formation  
The results of Chapter 2 suggest excessive tissue was mainly cartilage, which might be 
laid down through chondroidal ossification. Cartilage formation is initiated as mesenchymal 
condensation followed by chondrocyte proliferation, hypertrophy and eventually 
mineralisation. Several in vitro studies suggest that PGE2 is not critical in regulating the 
initial mesenchymal condensation and proliferation in primary mouse limb bud [285] and 
human mesenchymal stem cells [286]. PGE2 might be more important in the later stage of 
chondrogenesis since in vitro stimulation of limb bud mesenchymal stem cells with PGE2 
reduced the hypertrophy and calcification without affecting chondrocyte differentiation 
[287]. These studies suggest that PGE2 may have more important roles in terminal 
chondrocyte differentiation and ossification. Therefore, blocking EP4 signalling may only 
prolong the process of chondroidal ossification but not prevent the initiation of excessive 
tissue formation.  
4-4.4 Treatment outcome is influenced by drug delivery  
The lack of efficacy in the current study might be due to failed drug delivery; however, we 
did not include a positive control to demonstrate the activity of compounds. The drug 
preparation‎ and‎ dosage‎ were‎ according‎ to‎ the‎ manufacturer’s‎ instruction.‎ Therapeutic‎
efficacy of these compounds at these doses via these delivery routes has been observed 
in models of inflammatory disease (personal communication). Diet containing 400 ppm of 
ONO-AE2-227 has been shown to reduce the aberrant crypt foci formation [276, 288]. Oral 
gavage in this experiment should allow more consistent drug intake compared to diet; 
however, this compound has not been extensively studied in vivo. Moreover, the volume of 
gavage had been shown to increase serum corticosteroid levels compared to sham 
gavage [289]. Therefore, although the control PGISp mice were handled and scored daily, 
treatments with daily placebo by gavage or subcutaneous injection should be performed in 
an ideal experimental design.    
The efficacy of EP4 agonist and antagonist could have been specifically measured by 
assaying changes in tissue cAMP levels by ELISA [290] or the phosphorylation of PKA, 
PI3K and AKT using Western blotting of joint tissue extracts. Unfortunately, neither axial 
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skeleton nor peripheral joints were collected for such assays. Indomethacin has been 
shown to down-regulate PGE2 expression in paws [291] and plasma [292] at lower doses 
and in a shorter treatment duration compared to the present study; therefore efficacy was 
anticipated. Measuring PGE2 level in either plasma or joints would have provided proof of 
NSAIDs efficacy, a control measure that would be undertaken in future studies.  
4-4.5 Mouse strain might affect treatment outcome 
It is known that BALB/c mice have Th2-polarised immune responses because of higher 
production and sensitivity to PGE2, which decreases the production of Th1 cytokine, IFN- 
and IL-12 [254, 293]. IL-4 is known to be protective in PGISp mouse model and the lack of 
IL-4 increases arthritis penetrance and accelerates disease progression [183]. This 
somewhat overcomes the protective nature of the pro-Th2 background. However, if IL-4 is 
involved in the protection elicited by the treatments, the absence of IL-4 in our model 
would have diminished the effects. Although IL-4 expression is not the primary target of 
PGE2/EP4 signalling, how PGE2/EP4 signalling affects immune responses in the absence 
of IL-4 remains unknown.   
4-4.6 Conclusion 
An EP4 agonist and antagonist did not have any significant impact on disease progression 
in the PGISp mice. However, without confirmation of successful drug delivery no definitive 
conclusions could be drawn from the current study. This study also revealed that the large 
degree of inter- and even intra-mouse disease variability of the PGISp model raises 
concerns regarding its usefulness for therapeutic testing. This contrasts with the 
appropriateness of this model with respect to recapitulation of AS disease feature and 
progression patterns (Chapter 2). Therefore, confirmation of the role of EP4 in 
inflammatory processes contributing to AS remains unknown although it seems evident 
there are no strong protective effects of this treatment approach.  
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4-5 Tables 
Table 4-3: p values compared to untreated mice (Mann-Whitney analysis)  
Treatment  ONO-AE1-329 
(mg/kg/day) 
ONO-AE2-227 
(mg/kg/day) 
hPTH 1-34 
(g/kg/5 
days/ week) 
IND 
(mg/kg/day) 
Dosage  0.05 0.1 0.3 10 20 30  30  2  
Day of disease 
onset  
0.3889 
 
0.0397 0.7511 
 
0.5000 
 
0.3889 
 
0.8333 
 
- - 
Incidence  0.3968 0.8889 0.8413 0.6349 > 0.9999 0.9524 0.7778 0.8571 
Inflammation  0.7143 0.8016 0.4603 0.8016 0.8016 0.2857 0.1667 0.9048 
Disc destruction  0.2857 0.9444 0.7143 0.8968 0.6667 0.2857 0.4127 0.2857 
Bone erosion 0.127 0.9444 0.4127 0.6667 0.2222 0.7143 0.4524 0.381 
Cartilage damage  0.2857 0.6667 0.873 0.6667 0.3095 0.5556 0.6825 0.2857 
Excessive tissue 
formation 
0.1111 0.4524 > 0.9999 0.246 0.6667 0.6032 0.127 0.6667 
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Treatment  ONO-AE1-329 
(mg/kg/day) 
ONO-AE2-227 
(mg/kg/day) 
hPTH 1-34 
(g/kg/5 
days/ week) 
IND 
(mg/kg/day) 
Dosage  0.05 0.1 0.3 10 20 30  30  2  
Ectopic 
chondrocyte 
formation  
0.1905 0.4603 0.7857 0.1032 0.5873 > 0.9999 0.4127 0.9524 
Serum IL-17 0.7429 
 
0.4000 
 
0.1429 
 
0.6786 
 
0.5714 
 
0.2500 
 
0.2286 
 
- 
Serum CRP 0.7302 
 
0.5317 
 
0.4156 
 
0.1111 
 
0.4127 
 
0.4127 
 
> 0.9999 
 
0.2500 
 
Lumbar BMD 0.8750 
 
0.0625 
 
0.0625 
 
0.4375 
 
> 0.9999 0.6250 
 
0.0159 
 
0.2500 
 
Lumbar 
BMC 
0.6250 0.3125 0.0625 0.8750 > 0.9999 0.6250 0.0079* 0.2500 
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Treatment  ONO-AE1-329 
(mg/kg/day) 
ONO-AE2-227 
(mg/kg/day) 
hPTH 1-34 
(g/kg/5 
days/ week) 
IND 
(mg/kg/day) 
Dosage  0.05 0.1 0.3 10 20 30  30  2  
Pelvic BMD 0.1905 0.5317 0.5065 0.5238 0.1508 0.8016 0.0159* 0.2500 
Pelvic BMC 0.2857 
 
0.0317* 0.4004 
 
> 0.9999 0.2222 
 
0.4127 
 
0.0159* 0.0357* 
Femoral BMD 0.8730 
 
0.3095 
 
0.4156 
 
> 0.9999 0.9444 
 
0.8016 
 
0.0159* 
 
> 0.9999 
 
Femoral BMC 0.6825 > 0.9999 0.1623 
 
0.6032 
 
0.0952 
 
0.5317 
 
0.0317* 
 
0.7143 
 
Mineralised tissue 0.6667 
 
0.4000 
 
> 0.9999 > 0.9999 Insufficient 
number. 
0.6667 
 
No images No images 
Cortical bone 
thickness 
> 0.9999 > 0.9999 > 0.9999 > 0.9999 Insufficient 
number 
> 0.9999 No image No image 
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Table 4-4: p values compared to N/N (Mann-Whitney analysis) 
 N/D D/N D/D 
Mineralised 
tissue 
0.6000 0.9000 0.0667 
 
Cortical bone 
thickness 
> 0.9999 > 0.9999 0.4167 
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Table 4-5: Sample size required to reaching significant difference  
Treatment  Untreated  ONO-AE1-329 
(mg/kg/day) 
ONO-AE2-227 
(mg/kg/day) 
hPTH 1-34 
(g/kg/5 
days/ 
week) 
IND 
mg/kg/day
) 
Dosage  - 0.05 0.1 0.3 10 20 30  30  2  
Day of 
disease 
onset(Mea
n ± SD) 
41.60±13.
09 
51.20±13.16 
55.60±8.98
9 
50.00±17.8
5 
48.40±10.01 
48.60±9.23
6 
38.40±15.1
8 
- - 
Sample 
size 
- 30 14 39 59 55 263 - - 
Disc 
destructio
n (Mean ± 
SD) 
1.958±0.8
828 
1.423±0.432
2 
2.056±0.55
54 
2.300±0.43
73 
1.814±0.871
7 
1.578±1.07
7 
2.460±0.42
13 
2.425±0.25
09 
1.210±0.65
05 
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Treatment  Untreated  ONO-AE1-329 
(mg/kg/day) 
ONO-AE2-227 
(mg/kg/day) 
hPTH 1-34 
(g/kg/5 
days/ 
week) 
IND 
mg/kg/day
) 
Dosage  - 0.05 0.1 0.3 10 20 30  30  2  
Sample 
size 
- 43 1272 105 589 85 49 56 22 
Excessive 
tissue 
formation 
(Mean ± 
SD) 
1.422±0.6
262 
0.7425±0.13
45 
1.270±0.51
39 
1.610±0.34
03 
0.9120±0.51
50 
1.112±0.81
09 
1.788±0.19
86 
2.048±0.39
39 
1.215±1.01
1 
Sample 
size 
- 14 266 174 24 64 46 16 144 
 121 
 
5 Chapter5: Early intervention ameliorates axial disease progression 
in the PGISp mouse model of AS 
5-1 Introduction 
The results of Chapter 2 suggest that inflammatory infiltrate initiates disc destruction, 
which might increase mechanical stress, destabilise the vertebral joints and lead to severe 
cartilaginous endplate damage. The subsequent excessive tissue formation, including the 
formation of bone, might be an aberrant repair response to disc destruction. Hence, we 
hypothesised that inflammation-derived disc destruction is a prerequisite of excessive 
tissue formation. Suppressing inflammation before leading to irreparable tissue damage 
might be an effective therapeutic approach for preventing or at least ameliorating 
progression of AS.  
Shorter disease duration is associated with better improvement in inflammatory symptoms 
and disease activity after anti-TNF treatment (Chapter 1, Table1-3). However, absolute 
disease diagnosis, fulfilling the modified New York criteria for AS, requires for diagnosis 
that the patient develops radiographic evidence of sacroiliac disease including erosions 
and sclerosis [294]. Due to this criterion, diagnosis is not confirmed until disease is well 
established, and consequently appropriate treatment is frequently delayed until significant 
damage has already occurred. Moreover, it is also difficult to unequivocally prove the 
absolute benefit of therapeutic approaches in AS as it is unethical to prescribe placebos to 
patients for long-term studies to observe the nature of disease progression. Therefore, 
there is potentially great value in AS animal models for testing the benefits of early 
treatment interventions.  
TNF‎blockers‎are‎used‎as‎the‎“gold-standard”‎therapy‎in‎AS‎patients.‎Etanercept‎(ETN)‎is‎
a commercial TNF blocker synthesised as a fusion of the soluble TNF receptor 2 and the 
constant region of human IgG1. The efficacy of ETN is well-established [295] and has 
shown in non-radiographic axial spondyloarthritis patients with disease duration shorter 
than five years [130], which represents a patient group with earlier disease.  
Local injection of glucocorticoid to inflamed joints, such as the sacroiliac joints, effectively 
reduces local inflammation in AS patients [115, 296]. Intravenous methylprednisolone 
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pulse injection significantly improves clinical symptoms, pain, stiffness, serum ESR and 
CRP within one week in established AS patients, and the effects last for an average of 12 
weeks [297]. Only one pulse of methylprednisolone at 1 mg significantly reduced pain and 
improved spinal mobility in AS patients with severe pain within 24 hours, and four pulses 
prolonged the improvement up to ten months [298]. Oral prednisolone (PRD) treatment at 
50 mg/day reduced serum CRP level and improved the clinical outcomes of AS patients in 
a two-week clinical study [299]. These studies showed favourable results of local as well 
as systemic glucocorticoid treatment in AS patients.  
The combination of these two effective anti-inflammatory drugs, TNF inhibitors and 
glucocorticoids, was selected to achieve strong anti-inflammatory effects in the present 
study. A prophylactic treatment is not practical in the clinic, and it cannot differentiate 
whether the efficacy is due to blockade of disease onset or inflammation-induced disc 
destruction. The goal of the present study was not to prevent inflammation but to prevent 
the subsequent disc destruction. Hence, we chose an early intervention approach rather 
than a prophylactic treatment regimen. Since there are no reliable methods or markers to 
detect spinal inflammation in vivo, the timing of treatment commencement was selected 
according to the findings of Chapter 2. We allowed mice to develop inflammatory 
responses and started intervention at the point where we predict mild spondylitis will have 
developed without pronounced tissue erosion or excessive tissue formation. We 
hypothesized that early intervention with potent anti-inflammatory therapy would inhibit or 
slow down disease progression.  
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5-2 Materials and methods 
5-2.1 Animal experiments 
  IL-4-/- females with body weights 17-20.6g were included in this study. Protocol for 
disease induction was the same as Chapter 2. PGISp mice were treated with vehicle, ETN 
alone or ETN plus PRD (ETN+PRD). ETN (kindly provided by Pfizer, NY, USA) was 
administered at 2 mg/kg by subcutaneous injection 3 times a week. PRD was administered 
at 1.5 mg/kg/day by a slow-release pellet (Innovative Research of America, Sarasota, FL, 
USA) implanted subcutaneously. Vehicle group were treated with PBS by subcutaneous 
injection with or without placebo pellets. All treatments started 3 days after the third PG 
injection and continued for 2 or 6 weeks as described in Figure 5. 1A.  
5-2.2 Peripheral arthritis 
  The peripheral scoring regimens used were the same as in Chapter 4 of this thesis. 
5-2.3 Histology 
The histology and scoring regimens used were the same as in Chapter 2 of this thesis.  
5-2.4 Statistics and sample size calculation 
Mann-Whitney analysis was used to test statistically significant differences. P values less 
than 0.05 were considered significant differences. The relationships between two data 
outputs were determined by Spearman correlation. All the statistical analyses were 
performed using PRISM 6 (GraphPad Software, La Jolla, CA). The significant differences 
between the proportions of treatments were determined by Z-test 
(http://epitools.ausvet.com.au/content.php?page=home) through one-tailed distribution 
calculation with the significance level 0.05. Sample size calculation was conducted using a 
power calculator (http://powerandsamplesize.com/) with a significance  of 0.05 and power 
of 1-=0.8.  
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5-3 Results 
5-3.1 ETN+PRD delayed symptom onset and suppressed peripheral 
arthritis  
In the PGISp AS model, clinical scores fluctuate; hence the onset of disease was defined 
as when single paw recorded a positive score three consecutive scores (scored every 
other day). As reported in early chapters, the onset of peripheral arthritis varied between 
individual mice, with the earliest onset observed from 4 weeks post priming (Figure 5.1B). 
In vehicle-treated mice, peripheral arthritis score steadily increased from 4 weeks followed 
by an accelerated exacerbation from 6.5-8 weeks and then stabilization of peripheral score 
from 8 weeks post priming onwards (Figure 5.1B, black line). The mice treated with the 
ETN+PRD treatment had similar peripheral arthritis onset and progression until 6 weeks 
post-priming (Figure 5.1B, red), which was the treatment initiation point (Figure 5.1A). 
When compared to vehicle-treated mice, ETN+PRD-treated mice had significantly lower 
peripheral scores from week 7 to 9 post priming (Figure 5.1B, red, p<0.05). From 9 weeks 
onwards, peripheral disease appeared to escape drug-induced suppression, as peripheral 
scores of ETN+PRD-treated mice increased steadily and equalized with vehicle-treated 
mice at approximately 10.5 weeks post priming (Figure 5.1B, red and black lines). The 
mice in the ETN alone group all had onset prior to treatment initiation and more severe 
peripheral arthritis from week 5 (Figure 5.1B, blue lines). Surprisingly, ETN alone did not 
suppress clinical scores immediately; however, it seemed to retard disease progression as 
the peripheral arthritis score from approximately 8 weeks post priming showed a declining 
trend when compared with the vehicle-treated group (Figure 5.1 B, blue line). 
The variation in disease onset characteristic to this model (see Chapter 2) and the 
arbitrary treatment initiation point may have influenced treatment impacts. To more 
specifically investigate whether ETN+PRD delayed PGISp disease onset and/or 
suppressed inflammatory symptoms, we grouped mice based on whether definite 
peripheral disease symptoms were detected prior to treatment (onset Pre-RX) or if 
peripheral arthritis was only detected after treatment was initiated (onset post-RX ) (Table 
5-1). Mice with no peripheral arthritis before the end of this study might develop peripheral 
symptoms if the time course was prolonged. Conservatively, these mice were grouped in 
onset post-RX group during analysis. In onset pre-RX mice, average peripheral arthritis 
 125 
 
scores did not reveal consistent significant suppression of disease, likely due to the broad 
variance in rate of disease progression between mice in this AS model (Figure 5.1C, red). 
A treatment effect of ETN+PRD was more evident when the difference in peripheral 
arthritis scores before and after treatments in individual mice were examined (Figure 
5.1D). Progression of arthritic symptoms was significantly suppressed across the majority 
of the treatment period by ETN+PRD treatment (Figure 5.1D, red). ETN alone neither 
dramatically decreased peripheral disease nor altered disease progression (Figure 5.1D, 
blue). The peripheral disease in this group was stable for four weeks before a slowly 
increasing.  
Within the onset post-RX group, all vehicle-treated mice developed peripheral arthritis 
within 2 weeks after the third PG immunization (Figure 5.1E, F. Black line), whereas 
ETN+PRD treatment significantly delayed disease onset for 3 weeks (Figure 5.1E. 
Redline). This was verified by stable arthritis scores in ETN+PRD treated mice over the 
same period (Figure 5.1F, red line). However, from 9 weeks post priming, there was no 
significant difference in peripheral arthritis score between vehicle and ETN+PRD treated 
mice within the onset post-RX group (Figure 5.1E) and the‎ “change in arthritis” score 
suggested similar disease severity once the initial onset delay was overcome (Figure 
5.1F). The results suggest that while ETN+PRD treatment delayed peripheral disease 
onset and suppressed the severity of arthritic symptoms, and that it did so more effectively 
than ETN alone, the combined treatment did not completely inhibit inflammation.  
Table 5-1: Percentage of mice in Pre-RX and onset post-RX groups 
 6-12 weeks 6-8 weeks 
 Vehicle 
(N=7) 
ETN+PRD 
(N=8) 
ETN 
(N=5) 
Vehicle 
(N=5) 
ETN+PRD 
(N=7) 
Onset pre-RX  57.1% 62.5% 100% * 40%  28.6%  
Onset post-RX   42.9%  25% 
 
0 40%  0* 
No peripheral 0 12.5%  0 20%  71.4% * 
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 6-12 weeks 6-8 weeks 
disease 
Total  7 8 5 5 7 
*p<0.05 compared to vehicle at the same time point 
 
 
Figure 5.1: Combination of ETN and PRD suppressed peripheral arthritis. 
(A) Axial disease was induced by intraperitoneal injection of PG as described in the 
Materials and Methods. PGISp mice were treated with vehicle, etanercept (ETN) (2mg/kg, 
3 times a week, subcutaneous injection) plus prednisolone (PRD) (1.5mg/kg/day, slow 
released pellet) or ETN alone (n=5-8/group). Treatment started 3 days after the third PG 
injection at week 6 and was continued until either week 8 or 12 post priming. (B) 
Peripheral arthritis progression of mice receiving vehicle (black), ETN+PRD (red) and ETN 
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(blue) represented as the sum of all four limbs scores per mouse. Arrow indicates the 
initiation of treatment. PGISp mice were divided into (C, D) onset pre-RX (E, F) and onset 
post-RX according to the sequence of treatment commencement and the onset of 
peripheral arthritis. (C) The raw peripheral scores as per in (A) and (D) change of 
peripheral score after treatment of onset pre-RX group mice. (E) The raw peripheral scores 
as per in (A) and (F) change of peripheral scores after treatment of onset post-RX group 
mice. Data was presented by mean ± SD. The statistical significance of data was analysed 
by Mann-Whitney analysis. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 ETN+PRD 
treatment compared with vehicle. # p<0.05 ETN alone compared with vehicle. 
 
5-3.2 ETN+PRD ameliorated axial disease 
We next examined whether the anti-inflammatory treatments, as per Figure 5.1A, can 
suppress axial disease progression. The average percentage of affected IVDs in 
ETN+PRD treatment groups (52.17% and 50.0% at week 8 and 12 respectively), were not 
significantly different between the vehicle groups (50.85% and 60.25% at week 8 and 12 
respectively, Figure 5.2A). However, only the ETN+PRD treatment group contained 
animals with no evidence of axial disease (3/7 at 8 weeks and 2/6 at 12 weeks). 
ETN+PRD treatment significantly suppressed inflammation at both time points (Figure 
5.2B). All vehicle-treated mice had either peripheral or axial disease after treatment for 6-8 
week, while 40% of ETN+PRD-treated mice still had no detectable peripheral and axial 
disease (Table 5-2). Trends towards reductions in disc destruction (Figure 5.2C), bone 
erosion (Figure 5.2D), cartilage damage (Figure 5.2E) and excessive tissue formation 
(Figure 5.2F) were also seen in the ETN+PRD treatment group, although the differences 
were not significant compared to vehicle-treated mice. However, mice treated with ETN 
alone displayed similar axial disease progression compared to vehicle and significantly 
more severe disease in all outcomes compared to ETN-PRD treated mice (Figure 5.2 B-
E).  
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Figure 5.2: Combination of ETN and PRD suppressed spinal inflammation.  
(A) The percentage of affected joints in individual mice. Semi-quantitative histological 
scoring of the following disease features: (B) inflammation, (C) disc destruction, (D) bone 
erosion, (E) cartilage damage and (F) excessive tissue formation. Each point represents 
the average score of all IVD within a mouse. The results are presented as mean ± SD. The 
statistical significance of data was analysed by Mann-Whitney analysis. **p<0.01, *p<0.05 
compared with indicated groups. 
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Table 5-2: Percentage of mice developing peripheral and/or axial disease 
Treatment 
duration 
6-12 weeks 6-8 weeks 
Treatment 
(mouse number) 
Vehicle 
(N=7) 
ETN+PRD 
(N=8) 
ETN 
(N=5) 
Vehicle 
(N=5) 
ETN+PRD 
(N=7) 
Both peripheral 
and axial 
100% 
 
62.5%  100%  60%  42.85%  
Peripheral disease 
only 
0 25% 0 0 0 
Axial disease only 0 12.5% 0 40%  14.3% 
No disease 0 0 0 0 42.85%* 
Total mouse 
number 
7 8 5 5 7 
*p<0.05 compared to vehicle at the same time point 
 
5-3.3 Axial disease is independent of peripheral arthritis 
According to our hypothesis, treatment should be more effective for preventing 
osteoproliferative spinal disease when commenced early in disease evolution. As the point 
of onset of axial disease could not be determined without sacrificing mice, we used the 
peripheral arthritis score as a surrogate of disease evolution to determine when to initiate 
treatment. Mice were sub-grouped according to the onset of peripheral disease. Early 
onset of peripheral disease did not lead to more severe axial disease in either vehicle or 
ETN+PRD treatment group (Figure 5.3A-F, pre versus post). In both pre-RX and post-RX 
groups, ETN+PRD therapy demonstrated a trend toward reduced incidence, inflammation, 
disc destruction, bone erosion, cartilage damage and excessive tissue formation 
compared to vehicle (Figure 5.3A-F, red) with non-significant differences. As this sub-
grouping resulted in smaller group sizes, this greatly reduced statistical power of the 
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experiment. Although most diseased mice presented with both peripheral and axial 
disease, there were individual mice that developed either only peripheral or only axial 
disease (Table 5-2), indicating independent involvement of the different disease sites, and 
that peripheral disease is not a totally reliable predictor of axial disease.  
 
Figure 5.3: Early intervention showed a trend toward reduction of axial disease 
independent of whether peripheral disease had early or late onset.  
PGISp mice receiving vehicle (black) and ETN+PRD treatment (red) were grouped 
according to the onset of peripheral arthritis. (A) Incidence of affected IVDs, and 
histological features of the following disease features: (B) inflammation, (C) disc 
destruction, (D) bone erosion, (E) cartilage damage and (F) excessive tissue formation 
were presented as mean ± SD. The statistical significance of data was analysed by Mann-
Whitney analysis.  
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5-3.4 Disc destruction is associated with disease severity  
Prevention of disc destruction was the main goal of the chosen anti-inflammatory 
treatments in the present study. However, Figure 5.2C shows that reduction of disc 
destruction score in ETN+PRD treatment did not reach significance. This was likely due to 
the presence of high and low disc destruction subgroups in both vehicle and ETN+PRD 
treatment groups (Figure 5.2C) and overall relatively small sample size. Disc destruction 
was strongly and positively correlated with inflammation, bone erosion, cartilage damage 
and excessive tissue formation in all PGISp mice treated for 6-12 weeks (Figure 5.4A). 
This was similar to both vehicle (Figure 5.4B) and ETN+PRD-treated mice (Figure 5.4C), 
but inflammation was not significantly correlated with disc destruction in either group. The 
correlation between disc destruction and bone erosion was less significant in the vehicle-
treated group (p=0.048) and became non-significant (p=0.15) in ETN+PRD treatment 
group (Figure 5.4C).  
 
Figure 5.4: Disc destruction is strongly associated with bone erosion, cartilage and 
excessive tissue formation.  
Correlation between disc destruction with Inflammation (black), bone erosion (red), 
cartilage damage (orange) and excessive tissue formation (blue) of (A) all PGISp mice 
treated with vehicle and ETN+PRD treatment from week 6 to 12, (B) only vehicle group, 
and (C) only ETN+PRD treatment. Statistical significance was analysed by Spearman 
correlation.  
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Since the stage of progression of axial disease at the initiation of therapy also likely 
effected the treatment outcome [202, 203, 205, 206] and we had shown that peripheral 
disease was not a full proof surrogate of axial disease (Figure 5.3 and Table 5-2), grouping 
based on disc destruction severity was then considered in the analysis. The mean disc 
destruction score in vehicle and ETN+PRD-treated groups,1.45 and 0.57 respectively, was 
set as the cut-off value to separate mice into low and high disc destruction groups: 
vehicle(L), vehicle(H), ETN+PRD(L) and ETN+PRD(H) (Figure 5.5).  
Analysis of low versus high IVD destruction subgroups within the treatment regimens 
demonstrated that there was a trend but no statistically significant difference in the 
average disc destruction score between vehicle (L) and vehicle (H) (Figure 5.5A, orange 
vs brown, p=0.0571). In contrast, the mean disc destruction score within the ETN+PRD (L) 
was significantly lower than the ETN+PRD (H) (Figure 5.5A, light green vs dark green, 
p<0.05). Subgrouping in this manner also showed that in mice with low disc destruction, 
irrespective of whether they were vehicle (Figure 5.5, orange vs brown) or ETN+PRD 
treated (Figure 5.5, light green vs dark green), the severity of inflammation (Figure 5.5B), 
bone erosion (Figure 5.5C), cartilage damage (Figure 5.5D) and excessive tissue 
formation (Figure 5.5E) tended to be lower. Significant reductions were observed between 
ETN+PRD (L) (light green) and ETN+PRD (H) (dark green) for all measures (p<0.05) 
except for inflammation (Figure 5.5B-E, p=0.0536). 
When comparing ETN+PRD (H) with vehicle (H) (Figure 5.5A, dark green vs brown, 
p<0.05), the mean disc destruction score within the ETN+PRD (H) was significantly lower 
than the vehicle (H). These observations imply that ETN+PRD treatment reduced disc 
destruction outcomes independent of variation of the disease severity course (mild or 
robust disease). Furthermore, ETN+PRD (H) was shown to reduce inflammation 
significantly (Figure 5.5B, dark green vs brown p<0.05) and bone erosion (Figure 5.5C, 
p<0.05). A trend toward reduced cartilage damage (Figure 5.5D, p=0.064) and excessive 
tissue formation (Figure 5.5E, p=0.064) was also observed in the ETN+PRD (H). 
Therefore, in the subgroup of mice that had more robust disease induction, ETN+PRD 
treatment was able to reduce axial disease and damage considerably.  
 133 
 
 
Figure 5.5: Combination of ETN and PRD reduced axial disease in more severely 
affected mice.  
PGISp mice in vehicle group were sub-grouped into low disc destruction (Vehicle (L), 
orange), and high disc destruction (Vehicle (H), brown) in relation to the average 
score,1.45. ETN+PRD-treated mice were split into low disc destruction, (ETN+PRD (L), 
light green), and high disc destruction (ETN+PRD (H) ,dark green) in relation to the 
average score, 0.57: Semi-quantitative histological scores for (A) disc destruction, (B) 
inflammation, (C) bone erosion, (E) cartilage damage and (F) excessive tissue formation. 
The results are presented as mean ± SD. The statistical significance of data was analysed 
by Mann-Whitney analysis. * p<0.05 compared with indicated group. 
 134 
 
5-4 Discussion 
The aim of this intervention project was to examine whether inflammation-induced disc 
destruction is the prerequisite for excessive tissue formation in the context of AS and 
whether interventions to reduce inflammation before it leads to deleterious structural 
damage would alter disease progression.  
The combination of strong anti-inflammatory drugs, ETN and PRD, was commenced 3 
days after the third PG injection, when about 50% of mice had developed detectable 
peripheral arthritis while the other half may be either unaffected or have subclinical 
inflammation. The early intervention with ETN+PRD treatment significantly delayed 
disease onset and ameliorated the progression of peripheral arthritis. All the vehicle-
treated mice developed either peripheral or axial disease in the 6-12 week group; while 
40% of ETN+PRD-treated mice in 6-8 week group did not have detectable peripheral or 
axial disease suggesting ETN+PRD treatment controlled inflammation for the first 2-3 
weeks. The histological analysis demonstrated that this transient suppressive effect in the 
early phase had led to a significant reduction of inflammation and a declining trend of disc 
destruction, cartilage damage, bone erosion and excessive tissue formation.  
Early diagnosis and initiation of disease prevention strategies have been suggested to 
retard syndesmophyte formation. Delaying anti-TNF treatment for more than ten years 
after onset resulted in higher radiographic progression rate than those who started anti-
TNF within ten years of onset [206]. The mean changes of mSASSS score after high-dose 
NSAID treatment for two years were 0.02 and 0.4 in patients with disease duration 5.5 
years [96] and 11.9 years [97] respectively. The presence of syndesmophytes when 
treatment commenced strongly predicted radiographic progression regardless of 
treatments [202, 203, 205, 206] suggesting that anti-inflammatory therapy is more effective 
in inhibiting radiographic progression before structural damage has been initiated. The 
results from HLA-B27/h2m transgenic rats also demonstrated that early treatment 
blocked chondroproliferation and activation of BMP signalling, but not delayed treatment 
[114]. The above studies and our results all support the concept that early intervention is 
beneficial for preventing the subsequent osteoproliferation.   
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Early intervention should have chances to prevent inflammation-derived disc destruction or 
ameliorate the ongoing process. The therapeutic window was short and varied between 
individual mice and even individual discs. If the disc was affected by more aggressive 
disease and destruction was not suppressed in time, it might compromise the treatment 
efficacy.   
Since the treatment and disc destruction both affect the outcome in the present study, 
subgrouping is required to separate the effects of treatment and disc destruction. We were 
unable to monitor the axial disease. Chapter 2 showed that the inflammation is upstream 
of all the following events, but the same inflammatory score might indicate either 
developing or declining phase of inflammation. Therefore, inflammatory scores were not 
well correlated with other features in either treatment group and could not be used as good 
indicator of disease.  
 Figure 5.3 showed that disc destruction was strongly and positively correlated with 
cartilage damage and excessive tissue formation in both vehicle and ETN+PRD-treated 
mice; therefore, it served a better indicator of disease severity in the present study. 
Presumably, PGISp mice that had more aggressive disease progression before treatment 
were more likely to develop more severe disc destruction at the end of this study. 
Subgrouping mice by the severity of disc destruction and comparing those had more 
robust disease in each treatment group showed that early intervention with ETN+PRD was 
able to significantly ameliorate inflammation, disc destruction, bone erosion and a trend 
toward cartilage damage and excessive tissue formation was also observed. It suggests 
that even in more severe disease, early intervention might still have the potential to 
ameliorate destruction and retarded excessive tissue formation. Power calculations 
demonstrated that the current study is underpowered and will require 21 mice to reach a 
significant difference. Since no study had showed that this dosage of combined ETN+PRD 
can‎ suppress‎ spondylitis‎ and‎ we‎ can’t‎ monitor‎ axial‎ disease‎ in vivo for treating axial 
disease in the PGISp mouse model, a small scale study like the present study is 
necessary to determine the sample size for future study.  
Since disc destruction is more likely to be the direct trigger of repair and subsequent 
excessive tissue formation, suppressing disc destruction might aid improving anti-
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inflammatory treatment outcome. The anti-resorption drugs, bisphosphonates, have been 
reported to reduce inflammation and improve disease activity in AS patients [232, 300-
305]. These studies were shorter than one year, which was not long enough to observe 
the effect on radiographic progression formation. Alendronate reduced cartilage 
degeneration and osteophyte formation in the anterior cruciate ligament transection 
(ACLT) rat model of OA [306]. Osteophyte formation in postmenopausal women was 
slowed down by alendronate treatment for 3-4 years [307]. Therefore, bisphosphonates 
might be able to reduce resorption, strengthen the joint structure and reduces osteophyte 
formation.  
Overall, our results support the hypothesis that early intervention with effective anti-
inflammatory treatment has the potential to suppress inflammation and reduce the 
following tissue destruction and excessive tissue formation. Combining anti-resorption 
agents with anti-inflammatory treatment might be another therapeutic approach for 
suppressing syndesmophyte formation in AS. 
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6 Final discussion and future direction 
6-1 Final discussion  
The association between inflammation and excessive bone formation is of great interest in 
the context of AS. Therapies aiming to relieve symptoms effectively reduce inflammation; 
however, their effects on syndesmophyte formation are limited (Table 1-5). The 
mechanisms triggering inflammation and regulating the inflammation-osteoproliferation 
transition remain poorly understood, largely due to the lack of relevant bone biopsies. 
Hence, an animal model is a necessary substitute for understanding the axial disease 
progression in AS.  
The PGISp mouse model is known to develop inflammation, extensive IVD destruction and 
excessive tissue formation in the axial skeleton [105, 176], but no study had characterised 
the disease progression or the correlation between inflammation, catabolic and anabolic 
features in this model.  
The in-depth histological analysis, conducted across a 40-week time course study in this 
thesis, demonstrated that PGISp disease manifests in a heterogeneous fashion at 
individual vertebral joints and between individual animals, similar to the broad range of 
disease severity seen in AS patients [212]. The early inflammation and advanced 
excessive tissue formation mimics the progression of AS in humans (Figure 6.1A). These 
characteristics support that the PGISp is a good model for understanding disease 
mechanisms, even though it results in experimental challenges. Overall this thesis 
achieved unparalleled characterisation of the PGISp mouse model, and provides insight 
into the mechanisms of disease progression in AS.  
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Figure 6.1 The model of disease progression and potential therapeutic strategies.  
(A) Inflammation and tissue formation are features of early and advanced stages 
respectively. (B) Proposed pathway mapping how initial inflammation leads to 
osteoproliferation and ankylosis. (C) The therapeutic window is in the inflammatory and 
IVD destruction phases. Early intervention with anti-inflammatory and anti-resorption 
treatments are the potential therapeutic strategies for AS.  
 
6-2 Contribution of this thesis 
6-2.1 Involvement of enthesis in the disease initiation and 
development   
Entheses are the sites where ligaments attach to bone and bear mechanical stress during 
movement. Enthesitis, inflammation in the entheses, is a characteristic feature of AS [308]; 
hence the link between where enthesitis occurs and where disease initiates has been long 
questioned.  
The interfaces between the anterior/posterior longitudinal ligaments and annulus fibrosus, 
spinal entheses, were sites where inflammatory infiltrates initially appeared in the PGISp 
model. Spinal inflammation has also been reported in similar regions in the HLA-B27/h2m 
transgenic rats [138] and curdlan-treated SKG mice [160]. In more advanced stages, 
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excessive tissue, ectopic chondrocyte and bone formation features occurred in similar or 
adjacent anatomic positions including the enthesis at the anterior/posterior longitudinal 
ligaments and nearby cortical bone surfaces. These observations provide strong support 
that spinal enthesis is highly involved in PGISp disease development and infer support for 
similar pathological mechanisms in AS patients [169].  
6-2.2 Mechanisms involved in excessive tissue formation 
Endochondral, intramembranous and chondroidal ossification have all been reported in AS 
sacroiliac joints [73] and SpA biopsies [78]. Direct transformation from cartilage to bone 
has recently been shown in the fused zygapophysial joints in AS patients [79]. The PGISp 
mice developed extensive excessive tissue around the destroyed IVD. These pathological 
tissues were primarily cartilaginous in morphology with high PG content (Chapters 2 and 
3) but also included foci of mineralised cartilage (Chapter 3). We also observed 
chondrocyte-like cells embedded in matrix containing low PG and low/no type I collagen, 
suggesting this tissue might be transitioning from cartilage to chondroidal bone within 
PGISp affected joints (Chapters 2 and 3). Other anabolic features, such as ectopic 
chondrocyte expansion (Chapter 2), osteophytes and ectopic bone (Chapter 3) occurred 
adjacent to the periosteum, implying the involvement of periosteal cells in PGISp ankylosis 
(Chapter 3).  
The morphology and distribution of ectopic bone and osteophyte imply the contribution of 
biomechanical input in driving the anabolic process in PGISp disease. Given the severity 
of disc destruction observed in many PGISp mice (Chapter 2) and other structural changes 
(Chapter 3), it is obvious that axial skeleton biomechanics would be substantially altered in 
affected mice. Biomechanical stress has been shown to be associated with enthesitis in 
TNF∆ARE‎mice‎and‎osteophyte‎formation‎in‎the‎collagen‎antibody-induced arthritis mouse 
model (CAIA) [169]. The present study suggests that both entheseal and non-entheseal 
biomechanical stress might play important roles in progression of spinal disease in PGISp 
mice, for not all the pathological bone developed from enthesis. More detailed 
investigation is required to define the specific changes that occur.  
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6-2.3 The association between inflammation and osteoproliferation 
In the PGISp mouse model, mesenchymal cell proliferation initiated when inflammatory 
infiltrates were still present, but excessive tissue formation continued to progress after 
inflammation resolution. No colocalisation of severe inflammation and extensive excessive 
tissue formation was observed. Therefore, it was concluded that these two features do not 
initiate and progress in parallel in this model (Figure 6.1A).  
Severe inflammation was observed associated with IVD destruction (Chapter 2) and was 
highly suggestive of the inflammatory process mediating disc destruction. The severity of 
disc destruction was positively correlated with cartilage damage, bone erosion, and 
excessive tissue formation (Chapter 5). IVDs separate vertebrae and play important roles 
in bearing compressive loads [309]. As discussed above, IVD destruction would alter 
mechanical stresses throughout the spine, but particularly at the IV joints, and we propose 
that these mechanical changes are a major driver of excessive tissue formation. 
Therefore, vertebral joint inflammation triggers a cascade of events that ultimately causes 
anabolic changes within the axial skeleton of PGISp mice (Figure 6.1B). Therefore, our 
characterisation of the PGISp model suggests that inflammation is required for the 
subsequent excessive tissue formation and eventually spine ankylosis. 
This concept was verified in the PGISp mouse model by an early aggressive intervention 
study conducted in Chapter 5. The PGISp mice were treated with a combination of two 
strong anti-inflammatory treatments, etanercept and prednisolone (ETN+PRD). Treatment 
was commenced early in disease, a stage at which we anticipated that mice would have 
developed axial inflammation but limited disc destruction. The present study showed that 
early intervention with ETN+PRD significantly suppressed inflammation and demonstrated 
a trend in the reduction of disc destruction as well as excessive tissue formation (Chapter 
5). These results support the hypothesis that inflammation is required for excessive tissue 
formation.  
6-2.4 Clinical implications   
Clinical studies have shown that patients with shorter disease duration usually have a 
greater improvement in disease activity after anti-TNF treatment (Table 1-3). Anti-TNF 
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treatment might retard radiographic progression in AS (Table 1-6), however AS patients 
who have already developed syndesmophytes tend to show more radiographic 
progression regardless of their treatment [202, 203, 205, 206]. The above studies suggest 
that early intervention can lead to better therapeutic outcomes. 
Chapter 5 supports the promise that improved efficacy and outcomes will be achieved by 
early intervention with inflammation targeted drugs. This early intervention regimen might 
require changes in AS diagnosis requirements, becoming more aligned with starting 
treatment in non-radiographic axial SpA patients. Similar to AS patients, greater severity of 
disease at onset of treatment in PGISp mice compromised the treatment effects (Chapter 
5). However, even if mice had more severe disease, early intervention still retarded 
disease progression when compared to the vehicle treatment. Hence, early intervention 
strategy show promise for improving treatment efficacy. 
Therefore, the short therapeutic window falls between inflammation initiation and disc 
destruction (Figure 6.1C). However, it could be easily missed in AS patients, especially 
when there are no sensitive biomarkers or diagnosis criteria currently available. Slowing 
down disc destruction and joint damage might assist in attenuating excessive tissue 
formation if destructive processes have already been initiated.  
The mRNA expression analysis in Chapter 2 demonstrated that MMP-3 and MMP-13 were 
both upregulated in the PGISp spine. These enzymes are known to be associated with 
cartilage and disc degeneration and osteophyte formation in OA [310], and potentially 
mediated destructive phenotypes in the PGISp mouse model. Therefore, blocking cartilage 
degrading enzymes might have benefits toward preventing disc damage in AS.  
Anti-resorption therapy, bisphosphonates, has been demonstrated to reduce inflammation 
and decrease disease activity indices significantly in AS patients, although conclusions 
regarding their effects on syndesmophyte formation could not be drawn due to the short 
study duration [232, 300-305]. Reduction in osteophyte formation has been reported as a 
consequence of bisphosphonate treatment in other osteoporosis in postmenopausal 
women [307], and disease models, for example the anterior cruciate ligament transection 
rat model of OA [306]. Therefore, considering the observations made within this thesis, 
incorporating anti-resorption therapy in AS treatment, thereby reducing erosive damage 
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within effected areas, may alleviate biomechanical changes, strengthen the structure of 
spine and consequently reduce syndesmophyte formation.  
6-2.5 Limitation of the PGISp mouse model 
We acknowledge that the PGISp mouse model cannot perfectly replicate the disease 
symptoms of AS in human, as is the case with any animal model of disease. Female 
BALB/c mice have been shown to be more susceptible to PGIA/PGISp compared to male 
mice [311]. Gender effects might be attributed to genetics and interactions with the X 
chromosome have been shown to control disease susceptibility and onset whereas 
severity-associated loci were more strongly apparent in males [312]. Gender differences 
have also been reported in other disease models on the BALB/c background, such as 
curdlan-induced SpA in SKG mice [160] and ovalbumin-sensitised airway allergenic 
responses [313]. Difference of immune regulatory mechanisms between BALB/c and other 
strains and human might partially explain altered susceptibility of these models [313, 314]. 
IVD destruction in PGISp mice evolved to complete destruction much more rapidly than 
AS patients [219]. Therefore, the The syndesmophytes of AS patients usually develop 
from the vertebral corners at an angle <45° [233] and bridge two adjacent vertebral bodies. 
Osteophytes in PGISp mice grew outwards with morphologies differing from 
syndesmophyte. Subchondral bone lesions indicated by MRI lesions at vertebral corners in 
human disease were not seen in the PGISp mouse model. Nevertheless, compared to 
other current SpA/AS animal models, the data presented in this thesis confirms that the 
PGISp mouse model is still the best model to study the inflammation-osteoproliferation 
transition in AS patients.  
Shared features with patients is an advantage of this model, however, some of these 
“advantages”‎ limit‎ its‎ application‎ in‎ testing‎ therapies.‎ Similar‎ to‎ the‎ slow‎ progression‎ in‎
structural change in AS patients [232], it takes at least 24 weeks to establish extensive 
excess tissue in the PGISp mouse model. The variation caused by heterogeneous 
disease, which is also similar to what is seen in AS patients [315], greatly reduces the 
power of obtained data, as seen in Chapter 4 and Chapter 5. Therefore, time restraints 
and large sample sizes increase the difficulty of conducting experiments using this model. 
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The inadequate anti-inflammatory effects of ONO-AE1-329, the EP4 antagonist used in 
Chapter 4, indomethacin (Chapter 4) and etanercept alone (Chapter 5) suggest that very 
potent and perhaps non-specific anti-inflammatory treatments are required to suppress the 
inflammation in this model. Thus dissection of minor or partially compensated disease 
pathways would be extremely difficult to achieve using the PGISp model. Nevertheless, if 
a treatment successfully suppresses inflammation in this model, it might have a greater 
chance of suppressing inflammation in patients that are also often refractory to many anti-
inflammatory treatment regimens.   
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6-3 Future directions 
6-3.1 Improving methodology  
Histological analysis was the main assessment of axial disease in the present study. It is 
suitable for in-depth analysis, particularly for characterising the inflammation, erosion and 
cartilaginous tissue formation. However, it is not ideal for studying bone structural change. 
On the contrary, CT analysis has the advantages of studying changes in bone. In the 
future experiments, both histology and CT analysis should be performed to provide more 
information about the mechanisms behind abnormal bone formation. A serial histology and 
IHC staining analysis could be performed to identify potential signalling pathways. The size 
of osteophyte and ectopic bone formation using CT imaging could be used to classify 
stages and detailed histological examination could distinguish types of ossification. 
Candidate pathways that had been reported in osteophyte formation, such as Wnt and 
BMP that had been discussed in section 1-3.2, can be tested with IHC especially in 
samples at the early tissue formation stage. 
However, due to highly variable disease progression in this model and multiple factors 
contributing to disease development (eg, inflammation, mechanical stress, various cell 
types), targeting a single pathway either by genetically modified animal models or 
molecules might not be an effective strategy to verify the involvement of any particular 
signalling pathways.    
6-3.2 Incorporating anti-resorption therapies with present early 
intervention treatment 
We and other clinical studies have pointed out that early intervention in AS patients might 
improve not only inflammatory symptoms, but also excessive tissue formation. It leads to a 
number of future directions in this field. First of all, developing sensitive diagnostic tools 
and criteria are required for accurately and early identifying AS patients. Secondly, anti-
inflammatory therapies need to be able to suppress inflammation effectively without 
leaving subclinical inflammation that might continue causing IVD or structural 
destruction/destabilization. GWAS suggests a long list of candidates that might be 
important in regulating disease development (Table 1-1). Unfortunately, Chapter 4 did not 
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provide enough evidence in support of or against whether PTGER4, a candidate gene 
identified by our group [51], is a good therapeutic target. However, there is no doubt that 
more functional studies are required to evaluate these candidate genes. Finally, preventing 
structural damage and ankylosis is the ultimate goal; therefore, it is worth testing whether 
combining anti-inflammatory and anti-resorption therapies, such as bisphosphonates, 
might enhance the efficacy of anti-inflammatory treatments. These could also be coupled 
with approaches that provide biomechanical support to a destabilized axial skeleton. 
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8 Appendix 
Representative images of each histological score criteria. 
 
Appendix Figure1: Inflammatory scores.  
(A) Score 1: Minor infiltration of inflammatory cells at the periphery of the joint. Black 
arrows point to inflammatory infiltrates. (B) Score 2: Moderate infiltration – inflammatory 
pannus < 50% joint area. (C) Score 3: Marked infiltration – inflammatory pannus > 50% 
joint area. (D) Score 0: inflammatory score 0 can be given to an IVD with normal 
morphology or advanced disease. The representative image shows an affected IVD 
without inflammatory cells remain around in IVD space. Scale bar: (A) 400 m, (B) 300 
m, (C) 600 m, (D) 300m. 
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Appendix Figure 2: IVD destruction scores.  
(A) Score 1: Less than 50% disc destruction. (B) Score 2: more than 50% disc destruction. 
Black arrowhead indicates remnant IVD tissue. (C) Score 3: Total disc destruction/only 
necrotic disc left.  Original IVD space is indicated by blue arrows. Scale bar: (A) 500m, 
(B) 300m, (C) 400m.  
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Appendix Figure 3: Cartilage damage.  
(A) Score 1: Some erosion of endplate cartilage and/or growth plate cartilage (black 
arrowhead). (B) Score 2: Severe loss of articular cartilage and some growth plate cartilage 
damage. Black lines outline the interface between endplate and growth plate cartilage. 
Most endplate cartilage (between IVD space and black line) was severely eroded; whereas 
the thickness of growth plate cartilage remained. (C) Score 3: Severe loss of endplate 
cartilage and severe growth plate cartilage damage. Yellow line indicates subchondral 
bone surface that was still covered by growth plate and endplate cartilage. All other 
endplate and growth plate were damaged. Scale bars: (A-B) 300 m, (C) 200m. 
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Appendix Figure 4: Bone erosion scores.  
(A) Score 1: One or a few small areas of resorption in original vertebral bone. (B) Score 2: 
Numerous areas of obvious focal resorption in original vertebral bone or several areas of 
severe destruction. Black arrows indicate erosion. (B) Scale bar: (A) 200m, (B) 400m. 
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Appendix Figure 5: Excessive tissue formation scores.  
(A) Score 1: Mesenchymal cell invasion/ expansion. Black arrowheads indicate 
mesenchymal cells that present fibroblast morphology and lack of proteoglycan. (B) 
Moderate fibrocartilage formation (<50% of the original disc area) (C) Extensive 
fibrocartilage formation (>50% of the original disc area). Scale bars: 300 m. 
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Appendix Figure 6: Ectopic chondrocyte formation scores. 
(A) Score 1: single small area. (B) Score 2: single large area. (C) Score 3: multiple areas.  
Arrow heads indicate chondrocytes expanding on vertebral bone. Scale bars (A-B) 300 
m, (C) 400m. 
